

# BMJ Open

## Comparison of the automated rapid plasma reagin (RPR) test versus the conventional RPR card test in syphilis testing

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005664
Article Type:	Research
Date Submitted by the Author:	10-May-2014
Complete List of Authors:	Lee, Jong-Han; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lim, Chae Seung; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lee, Min-Geol; Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea, Kim, Hyon-Suk; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Infectious diseases, Diagnostics
Keywords:	Public health < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES, IMMUNOLOGY

SCHOLARONE™  
Manuscripts

only

1  
2  
3  
4 **Original article**  
5  
6  
7

8 **Comparison of the automated rapid plasma reagin (RPR) test versus the conventional**  
9 **RPR card test in syphilis testing**  
10  
11

12  
13  
14  
15 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>  
16  
17

18  
19  
20 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

21 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

22 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Correspondence: Hyon-Suk Kim

34 E-mail: kimhs54@yuhs.ac

35  
36  
37 Tel: (+82) 2-2228-2443

38  
39 Fax: (+82) 2-364-1583

40  
41  
42 Department of Laboratory Medicine, Yonsei University College of Medicine

43  
44 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea  
45  
46  
47

48 Running title: Automated RPR test for syphilis testing

49  
50 Number of words: 1,903; Number of abstract: 262

51  
52  
53 0 Figures, 5 Tables, and 16 References  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** Method comparative study using clinical remnant specimens in a single institute

**Participants:** A total of 112 serum samples including 59 TPPA- (Treponemal pallidum particle agglutination) positive and 53 TPPA-negative specimens were collected for this evaluation.

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the auto RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed higher positivity than the automated RPR test, whereas the automated RPR test showed higher seronegative changes (43.5%, 10/23) than the RPR card test (4.3%, 1/23) after syphilis treatment.

**Conclusions:** The automated RPR test showed a lower sensitivity compared to the manual RPR test when comparing TPPA, but showed higher seronegative conversion after treatment

1  
2  
3  
4 than the conventional RPR card test. The automated RPR test may be more useful to monitor  
5  
6 treatment response than the conventional RPR card test.  
7  
8

9 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement  
10  
11

### 12 13 14 **Strengths and limitations of this study** 15

- 16  
17  
18 ■ Automated rapid plasma regain (RPR) tests have been introduced but variable results  
19  
20 were reported when comparing the automated test to conventional RPR card tests.  
21  
22
- 23  
24 ■ The automated RPR test showed a lower sensitivity compared to the manual RPR test  
25  
26 when comparing TPPA.  
27  
28
- 29  
30 ■ The automated RPR showed higher seronegative conversion after treatment than the  
31  
32 conventional RPR card test. The automated RPR test may be more useful to monitor  
33  
34 treatment response than the conventional RPR card test.  
35  
36
- 37  
38 ■ Limitations of this study should be considered, including its small sample size and not  
39  
40 categorized patients group according to the stage of syphilis infection.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have reached a plateau.<sup>1</sup> Still, syphilis is an important infectious disease because it can cause serious health problems including neurosyphilis and congenital infection. Therefore, appropriate screening, confirmation, and follow-up protocols<sup>2-4</sup> should be well established. Serological analysis of non-treponemal reagin tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, and fluorescent treponemal antibody absorption test (FTA-ABS) have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2,5,6</sup> A non-treponemal reagin test is still recommended by the CDC to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been widely used, the VDRL and RPR methods. RPR is the most common first line non-treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have been introduced but variable results were reported when comparing the automated test to conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the conventional RPR card test such as greater capacity to deal with large scale samples, minimal person-to-person variation, simple automated procedures, and rapid reports with good analytical performances. The aim of this study was to evaluate possible benefits of an automated RPR test compared to a conventional RPR card test in clinical application.

## METHODS

### Subjects

A total of 112 serum samples from 59 syphilis patients (48±21 year, Male to Female = 25:34) and 53 non-syphilitic controls (45±17 year, Male to Female = 27:26 )were collected from November 2012 to April 2013 and preserved at -70°C until analyses. Patients were not categorized according to syphilis stage due to the infrequency of syphilis patients. HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared with Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) according to the manufacturer's instructions. Seroconversion rates of each non-treponemal RPR tests were evaluated with 23 syphilitic patients who had medical histories of syphilis treatment.

### Serologic tests

#### Conventional RPR card test

Briefly, the principle of the conventional manual RPR card test is as follows: the Macro-Vue RPR Card test uses cardiolipin antigen with a carbon particle to detect reagin, an antibody-like substance present in the serum or plasma of syphilis patients. Reagin binds to the test antigen, which consists of cardiolipin-lecithin-cholesterol particles, causing macroscopic flocculation. Controls were established in each day's testing to confirm optimal reactivity of the antigen. Each step of the test procedure was followed according to the manufacturer's instructions.

### Automated RPR

HiSens Auto RPR LTIA is a latex turbidimetric immunoassay using latex particles coated with lecithin and cardiolipin. The latex particle reacts with the reagin in the serum of syphilis patients. 15- $\mu$ L serum samples were used for analysis and then 120  $\mu$ L Hisens auto RPR LTIA R1 (buffer) and 60  $\mu$ L Hisens auto RPR LTIA R2 (latex reagent containing cardiolipin-lecithin-cholesterol 1.0 mg/mL) were reacted within 10 seconds. The absorption of reaction at 600 nm was read after 5.3 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens auto RPR that were equal to or greater than 1.0 RPR unit (R.U.) indicated a reactive result to syphilis. A CA-400 (Furuno Electric Co., Ltd. Nishinomiya, Japan) photometric analyzer was used for the automated procedure and analysis.

### *Treponema pallidum* particle agglutination (TPPA)

The Serodia TPPA assay is based on the agglutination of colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain) antigen. For each specimen, a 100- $\mu$ L sample of diluent and 25  $\mu$ L of test specimen were mixed first, then 2-fold serial dilutions were made with 25  $\mu$ L of sample diluent. The 3rd well of the test plate was mixed with unsensitized particles, while sensitized particles from 4th well were serially mixed in the next wells with a plate mixer for 30 seconds. After a 2-hour incubation at room temperature, the result of the agglutination assay was read. The Serodia TPPA assay results were interpreted to compare the agglutination patterns of reagents and positive and negative controls. Sensitized particles (1:80 final dilution or greater) were considered to indicate a positive reaction. For quantitative results, the antibody titer was determined as being the final dilution showing a positive pattern.

### Statistical analyses

The percent agreement, kappa coefficient, between automated RPR test and manual RPR card test was calculated. The overall sensitivity and specificity of each test were calculated based on the data from TPPA results. Kappa values were used to categorize results as very good (0.81 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or poor (0 to 0.2).<sup>9</sup> The McNemar test was used to compare the seroconversion rate between the automated RPR test and the conventional manual RPR card test and was performed by IBM SPSS Statistics Version 20 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was considered as statistically significant.

### RESULTS

The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709, Table 1). The strength of agreement between the automated RPR test and manual RPR card test was considered to be moderate according to the kappa value scale. The specimens of both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR negative results (n=56) showed 85.7% (48/56) TPPA-negative results.

There were 24 discrepant results (21.4%) between the two kinds of RPR tests, including 22 negative cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the BD Macro-Vue RPR card test. Of these 22 discrepant results, 20 cases were TPPA-positive and 2 cases were TPPA-negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA test but negative in the BD Macro-Vue RPR card test. These 2 cases were negative in the TPPA test. There were 4 results with discrepancies between both of the RPR tests and the



1  
2  
3  
4 TPPA assay which were due to conditions other than syphilis infections (Table 2). The  
5  
6 strength of agreement between the auto RPR and manual RPR card tests was fair (kappa  
7  
8 value: 0.296 (59 TPPA positive results); 0.293 (53 TPPA negative results)) according to TPPA  
9  
10 results (Table 3).

11  
12 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
13  
14 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively.  
15  
16 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
17  
18 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
19  
20 gave a higher seronegative conversion rate after syphilis treatment, with a value of 43.5%  
21  
22 (10/23), than that of the conventional RPR card test, which was 4.3% (1/23,  $p=0.004$ ) by  
23  
24 McNemar test. Detailed comparison results of treated syphilis cases are described in Table 5.  
25  
26  
27  
28  
29

## 30 31 **DISCUSSION**

32  
33  
34  
35 Treponemal tests cannot discriminate between past infections, active disease, treated  
36  
37 patients, and non-treated patients. Patients who are treponemal test-reactive have positive  
38  
39 results for this test for the remainder of their lives, regardless of treatment or disease  
40  
41 activity.<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have been  
42  
43 treated during the primary or secondary stage of the disease. Usually, the titer showed a 2-  
44  
45 dilution decline after treatment.<sup>7</sup> Therefore, a guaranteed non-treponemal test is important for  
46  
47 clinical settings to manage syphilitic patients.  
48  
49

50  
51 We compared an automated RPR test with a conventional RPR card test including a TPPA  
52  
53 test. The TPPA test was reported to be as sensitive as the FTA-ABS test in primary syphilis  
54  
55 and as useful as the RPR test for monitoring therapy. The TPPA test is also less subjective  
56  
57  
58  
59  
60

1  
2  
3  
4 than the FTA-ABS and easier to read than the microhemagglutination assay for antibodies to  
5  
6 *Treponema pallidum* (MHA-TP).<sup>11</sup> TPPA has also been suggested to be applied in CSF to  
7  
8 diagnose neurosyphilis.<sup>12</sup> Although the BD Macro-Vue RPR card test showed a better  
9  
10 positivity than did the HBI HiSens Auto RPR LTIA test in syphilis screening, the automated  
11  
12 RPR test does have some advantages in the clinical settings. For example, the automated RPR  
13  
14 test reduced the workload and overall test turn-around time. It also can deal with greater test  
15  
16 quantities in a given time than the manual RPR card test, and does not require test experts.  
17  
18 Also, we noticed that the automated RPR test may be useful for monitoring treatment  
19  
20 response, especially if treponemal-specific tests are used for first-line detection of syphilis as  
21  
22 a reverse algorithm of syphilis screening. Recently, this reverse algorithm for syphilis  
23  
24 screening has been suggested as a first-line screening for syphilis because this approach may  
25  
26 be more sensitive and effective than the traditional algorithm<sup>3 4 6</sup> and could be automated.  
27  
28 However, the Centers for Disease Control and Prevention (CDC) still recommend screening  
29  
30 for syphilis with a non-treponemal test first, such as RPR.<sup>2</sup>  
31  
32  
33 The automated non-treponemal test has an additional important advantage over the  
34  
35 conventional manual non-treponemal test in addition to those previously described. Our study  
36  
37 presented that the automated RPR test showed earlier seronegative conversion than  
38  
39 conventional card RPR test in discrimination after syphilis treatment ( $p=0.004$ ). If we adopt  
40  
41 the reverse algorithm, it could be ideal in that the treponemal tests screen sensitively first and  
42  
43 then the non-treponemal tests accurately show negative in the treated cases. In this situation  
44  
45 we could use treponemal tests for first-line screening and non-treponemal tests for monitoring  
46  
47 the patients to see seronegative conversion more effectively after treatment.<sup>2 13 14</sup>  
48  
49  
50 Unfortunately, this study had a limited number of syphilitic patients due to low prevalence rate  
51  
52  
53 of syphilis and not been classified as each syphilis stage. Further, well designed studies will  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 be needed to clarify the serologic responses of automated RPR tests after treatment and  
5  
6 according to the stage of syphilis infection.  
7

8  
9 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
10  
11 some evaluations comparing RPR tests to VDRL tests were reported.<sup>8 15</sup> However, the results  
12  
13 were variable. Tomohiko et al. also suggested that when the automated serological testing  
14  
15 method is used in clinical settings, the same reagent should be consistently selected to  
16  
17 evaluate the changes in antibody titers because the manual serological testing method for  
18  
19 syphilis showed somewhat different results from those of the automated serological testing  
20  
21 methods.<sup>16</sup> In the current study, we also noted moderately consistent results between auto  
22  
23 RPR and manual RPR.  
24

25  
26 We found that the automated RPR has a greater processing capability within a limited time  
27  
28 and is more effectively applicable in a reverse syphilis screening algorithm. Through the  
29  
30 reverse syphilis screening algorithm, we could increase the detection sensitivity of syphilis  
31  
32 screening, and the relatively low sensitivity of the automated RPR test may be compensated  
33  
34 for by its rapid seronegative conversion after treatment.  
35  
36

37  
38 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
39  
40 specificity compared to the conventional manual RPR card test. However, the automated  
41  
42 RPR test may be more helpful to monitor the seroconversion responses to syphilis treatment,  
43  
44 especially in the reverse syphilis screening algorithm. Further large-scale studies including  
45  
46 patients well-categorized by syphilis stage are warranted to clarify the accurate diagnostic  
47  
48 efficiency of the automated RPR test.  
49

#### 50 51 52 53 **Author affiliations** 54 55 56 57 58 59 60

1  
2  
3  
4 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

5  
6 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

7  
8 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea

9  
10  
11  
12  
13 **Contributors**

14  
15 Hyon-Suk Kim designed and participated in all stages of the study. Jong-Han Lee participated  
16  
17 in statistical analyses and draft the manuscript. Chae Seung Lim and Min-Geol Lee helped to  
18  
19 consultations of this study. All authors read and approved the final manuscript.  
20  
21

22  
23  
24 **Funding**

25  
26 None  
27  
28  
29

30  
31 **Competing interests**

32  
33 None.  
34  
35  
36

37  
38 **Provenance and peer review**

39  
40 Not commissioned; externally peer reviewed.  
41  
42  
43

44  
45 **Data sharing statement**

46  
47 No additional data are available.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep* 2011;60:133-7.
- 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLIS Syphilis Serology Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 4 French P, Gomberg M, Janier M, *et al.* IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin Infect Dis* 2012;25:79-85.
- 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 8 Kim YS, Lee J, Lee HK, *et al.* [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab Med* 2009;29:331-7.
- 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.

- 1  
2  
3  
4 11 Castro RR, Prieto ES, Santo I, *et al.* Evaluation of the passive particle agglutination  
5 test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.  
6  
7  
8  
9 12 Castro R, Prieto ES, Aguas MJ, *et al.* Evaluation of the Treponema pallidum particle  
10 agglutination technique (TP.PA) in the diagnosis of neurosyphilis. *J Clin Lab Anal*  
11 2006;20:233-8.  
12  
13  
14 13 Romanowski B, Sutherland R, Fick GH, *et al.* Serologic response to treatment of  
15 infectious syphilis. *Ann Intern Med* 1991;114:1005-9.  
16  
17  
18  
19 14 Sena AC, White BL, Sparling PF. Novel Treponema pallidum serologic tests: a  
20 paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-  
21 8.  
22  
23  
24  
25  
26 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with  
27 conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.  
28  
29  
30  
31 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the  
32 manual and automated serological testing methods for syphilis. *J Dermatol*  
33 2012;39:355-61.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Licence for Publication statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.

**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)

Kappa= 0.565

95% confidence interval: 0.422 to 0.709

<sup>1)</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were negative in TPPA test.

<sup>2)</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.



**Table 2** Summary of the four patients showing discrepant results to treponemal test

Case No.	Age /Sex	RPR card test	Auto RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Table 3** Comparison of non-treponemal RPR tests according to Treponemal pallidum particle agglutination (TPPA) test results

TPPA positive (n=59)				TPPA negative (n=53)			
		HBI HiSens Auto RPR				HBI HiSens Auto RPR	
		Positive	Negative			Positive	Negative
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48
Number of observed agreements: 39 (66.1% of the observations)				Number of observed agreements: 49 (92.5% of the observations)			
Kappa= 0.296				Kappa= 0.293			
95% confidence interval: 0.118 to 0.474				95% confidence interval: -0.212 to 0.798			

For peer review only

**Table 4** Overall Results of non-treponemal RPR tests

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive	31	3
	Negative	28	50
Sensitivity		52.5%	(95% CI: 39.1 % to 65.7 %)
Specificity		94.3%	(95% CI: 84.3 % to 98.8 %)
Positive predictive value		91.2%	(95% CI: 76.3 % to 98 %)
Negative predictive value		64.1%	(95% CI: 52.4 % to 74.7 %)
	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive	51	3
	Negative	8	50
Sensitivity		86.4%	(95% CI: 75 % to 93.9 %)
Specificity		94.3%	(95% CI: 84.3 % to 98.8 %)
Positive predictive value		94.4 %	(95% CI: 84.6 % to 98.8 %)
Negative predictive value		86.2 %	(95% CI: 74.6 % to 93.8 %)

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1	0	1:5120	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

**STARD checklist for reporting of studies of diagnostic accuracy**  
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	4
<b>METHODS</b>			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	5
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	5
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	5
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	5
<i>Test methods</i>	7	The reference standard and its rationale.	6
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	5-6
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	5-6
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	N/A
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	5-6
	13	Methods for calculating test reproducibility, if done.	N/A
<b>RESULTS</b>			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	5
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	5
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	N/A
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	N/A
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	7
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	7
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	8-10

# BMJ Open

## Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR card test in syphilis testing

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005664.R1
Article Type:	Research
Date Submitted by the Author:	27-Aug-2014
Complete List of Authors:	Lee, Jong-Han; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lim, Chae Seung; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lee, Min-Geol; Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea, Kim, Hyon-Suk; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Infectious diseases, Diagnostics
Keywords:	Public health < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES, IMMUNOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Original article**  
5  
6  
7

8 **Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR**  
9 **card test in syphilis testing**  
10  
11

12  
13  
14  
15 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>  
16  
17

18  
19  
20 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

21 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

22 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Correspondence: Hyon-Suk Kim

34 E-mail: kimhs54@yuhs.ac

35  
36  
37 Tel: (+82) 2-2228-2443

38  
39 Fax: (+82) 2-364-1583

40  
41  
42 Department of Laboratory Medicine, Yonsei University College of Medicine

43  
44 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea  
45  
46  
47

48 Running title: Automated RPR test for syphilis testing

49  
50 Number of words: 2,140; Number of abstract: 274

51  
52  
53 0 Figures, 5 Tables, and 16 References  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** Method comparative study using clinical specimens in a single institute

**Participants:** A total of 112 serum samples including 59 TPPA- (*Treponema pallidum* particle agglutination) positive and 53 TPPA-negative specimens were included for this evaluation.

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the auto RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed higher seronegative changes (43.5%, 10/23) than the manual RPR card test (4.3%, 1/23) in treated patients.

**Conclusions:** The automated RPR test showed overall lower sensitivity compared to manual RPR test based on treponemal test, TPPA, probably due to higher seronegative conversion after treatment than the conventional RPR card test. So, the automated RPR test might be



1  
2  
3  
4 more useful to monitor treatment response than the conventional RPR card test, especially in  
5  
6 the reverse screening algorithm in syphilis testing.  
7  
8

9 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement  
10  
11

### 12 **Strengths and limitations of this study** 13 14

- 15 ■ Automated rapid plasma regain (RPR) tests have been introduced in clinical laboratories,  
16 so we compared the automated test to conventional RPR card tests.  
17
- 18 ■ The automated RPR showed overall lower sensitivity compared to the manual RPR when  
19 comparing to treponemal test, TPPA.  
20
- 21 ■ The automated RPR showed higher seronegative conversion after treatment than the  
22 conventional manual RPR. So, the automated RPR test may be more useful to monitor  
23 treatment response than the conventional manual RPR, especially in the reverse  
24 screening algorithm for syphilis testing.  
25
- 26 ■ Limitations of this study could be considered, including small sample size and the patient  
27 groups could not accurately categorized according to the stage because of low prevalence  
28 of syphilis infection in Korea.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have decreased, and the prevalence rate is still very low.<sup>1</sup> Even though, syphilis is an important infection because it can cause serious health problems including neurosyphilis and congenital infection. So, appropriate screening, confirmation, and follow-up protocols are well established.<sup>2-4</sup> Serological analysis of non-treponemal reagin tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, fluorescent treponemal antibody absorption test (FTA-ABS) and Treponema-specific antibody test have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2 5 6</sup> A non-treponemal reagin test is still recommended by the CDC to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been widely used, the VDRL and RPR methods. RPR is the most common first-line non-treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have been introduced but variable results were reported when comparing the automated test to conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the conventional RPR card test such as greater capacity to deal with large scale samples, minimal person-to-person variation, simple automated procedures, and rapid reports with good analytical performances.

The aim of this study was to evaluate the possible benefits of an automated RPR test

1  
2  
3  
4 compared to a conventional RPR card test in clinical application.  
5  
6  
7

## 8 **METHODS**

### 9 **Subjects**

10  
11  
12  
13  
14  
15 A total of 112 serum samples from 59 syphilis patients (48±21 years-old, Male to Female =  
16  
17 25:34) and 53 non-syphilitic controls (45±17 years-old, Male to Female = 27:26) were  
18  
19 collected after treponemal test completed from November 2012 to April 2013 in a university  
20  
21 hospital in Korea. Remnant sera from requested treponemal test after confirmation were  
22  
23 included and preserved at -70 °C until analysis. Patients were not categorized according to the  
24  
25 syphilis stage due to the infrequency of syphilis infection. True syphilis patients were very  
26  
27 rare because of its low prevalence in this country. There was a report that only 1,424 cases are  
28  
29 registered in Korean Centers for Control and Prevention (KCDC) in 2007.  
30  
31

32  
33 The automated RPR test was compared with manual card RPR Test (Becton Dickinson BD  
34  
35 Microbiology Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was  
36  
37 performed by a *Treponema pallidum* particle agglutination assay (TPPA) according to the  
38  
39 manufacturer's instructions. Seroconversion rates of each non-treponemal RPR tests were  
40  
41 evaluated with 23 syphilitic patients who had medical history of syphilis treatment.  
42  
43  
44  
45

### 46 **Serologic tests**

#### 47 **Conventional RPR card test**

48  
49  
50  
51 The Macro-Vue RPR Card test (Becton Dickinson BD Microbiology Systems, Sparks, MD,  
52  
53 USA) uses cardiolipin antigen with a carbon particle to detect reagin. Reagin binds to the test  
54  
55 antigen, which consists of cardiolipin-lecithin-cholesterol particles, causing macroscopic  
56  
57  
58  
59  
60

1  
2  
3  
4 flocculation. Controls were established in each testing to confirm optimal reactivity of the  
5 antigen. The test procedure was followed according to the manufacturer's instructions.  
6  
7  
8  
9

### 10 **Automated RPR**

11  
12 HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) is a latex turbidimetric  
13 immunoassay using latex particles coated with lecithin and cardiolipin. The latex particle  
14 reacts with the reagin in the serum of syphilis patients. The 15 µL serum samples were  
15 reacted with 120 µL Hisens auto RPR LTIA R1 (buffer) and 60 µL Hisens auto RPR LTIA R2  
16 (latex reagent containing cardiolipin-lecithin-cholesterol 1.0 mg/mL) in CA-400 autoanalyzer  
17 (Furuno Electric Co., Ltd. Nishinomiya, Japan). The CA-400 photometric analyzer was used  
18 for the automated procedure and analysis. The absorbance at 600 nm was read after 5.3  
19 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens auto RPR  
20 equal to or greater than 1.0 RPR unit (R.U.) were considered as reactive RPR. The upper  
21 detection limit was 20 R.U..  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 ***Treponema pallidum* particle agglutination (TPPA)**

38  
39 The Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) is based on the agglutination of  
40 colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain)  
41 antigen. For each specimen, a 100 µL sample of diluent and 25 µL of test specimen were  
42 mixed first and 2-fold serial dilutions were made with 25 µL of sample diluent. The sensitized  
43 particles were serially mixed in the next wells with a plate mixer for 30 seconds. After 2  
44 hours incubation at room temperature, the result of the agglutination assay was read. The  
45 Serodia TPPA assay results were interpreted by the agglutination patterns with positive and  
46 negative controls.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Statistical analyses

The percent agreement, kappa coefficient, of automated RPR test with manual RPR card test was calculated. The overall sensitivity and specificity of each test were calculated based on the data from TPPA results. Kappa values were used to categorize results as very good (0.81 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or poor (0 to 0.2).<sup>9</sup> The McNemar test was used to compare the seroconversion rate between the automated RPR test and the conventional manual RPR card test and was performed by SPSS Statistics Version 20 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was considered statistically significant.

## RESULTS

The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709, Table 1). The strength of agreement between the automated RPR test and manual RPR card test was considered to be “moderate” according to the kappa value scale. The specimens of both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR negative results (n=56) showed 85.7% (48/56) TPPA-negative results.

There were 24 discrepant results (21.4%) between the two RPR tests, including 22 negative cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the BD Macro-Vue RPR card test. And there were two false positive cases in HiSens Auto RPR LTIA test. Of these 22 discrepant results, 20 cases were TPPA-positive and 2 cases were TPPA-negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA test but negative in the BD Macro-Vue RPR card test. These 2 cases were negative in the TPPA test. There were

1  
2  
3  
4 4 results with discrepancies between both of the RPR tests and the TPPA assay which were  
5  
6 due to conditions other than syphilis infections (Table 2). The strength of agreement between  
7  
8 the auto RPR and manual RPR card tests was “fair” (kappa value: 0.296, 59 TPPA positive  
9  
10 results; 0.293, 53 TPPA negative results) according to TPPA results (Table 3).

11  
12 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
13  
14 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively.

15  
16 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
17  
18 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
19  
20 gave a higher seronegative conversion rate after syphilis treatment, with a value of 43.5%  
21  
22 (10/23), than that of the conventional RPR card test, which was 4.3% (1/23,  $p=0.004$ ) by  
23  
24 McNemar test. Detailed comparison results of treated syphilis cases are described in Table 5.  
25  
26  
27  
28  
29

## 30 31 **DISCUSSION**

32  
33 Manual RPR test has been used for decades, and recently the automated RPR test method  
34  
35 was launched and has been used because of its convenience in clinical settings. However,  
36  
37 there has been the need to thorough inspection and comparing results of this new automated  
38  
39 test to conventional manual RPR test in the diagnostic approaches. The treponemal test  
40  
41 results will not change even after treatment, and the patients live with positive results for the  
42  
43 remainder of their lives regardless of treatment or disease activity. Treponemal tests cannot  
44  
45 discriminate between the past infections, active disease, treated patients, and non-treated  
46  
47 patients.<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have  
48  
49 been treated during the primary or secondary stage of the disease. When the primary or  
50  
51 secondary stage of a first *T. pallidum* infection is treated, nontreponemal test titer should  
52  
53 show a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> Therefore, non-  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 treponemal test is important for managing the syphilitic patients.

5  
6 We compared an automated RPR test with a conventional RPR card test in the confirmed  
7  
8 patients' sera with TPPA. The TPPA test was reported to be as sensitive as the FTA-ABS test  
9  
10 in all the stages of syphilis and as useful as the RPR test for monitoring therapy. The TPPA  
11  
12 test is also known to be less subjective than the FTA-ABS and easier to read than the  
13  
14 microhemagglutination assay for antibodies to *Treponema pallidum* (MHA-TP).<sup>11</sup> TPPA has  
15  
16 also been suggested to be applied to CSF samples to diagnose neurosyphilis.<sup>12</sup>  
17

18  
19 In our study, the BD Macro-Vue RPR card test showed better sensitivity than did the HBI  
20  
21 HiSens Auto RPR LTIA test in syphilis screening. But, the automated RPR test does have  
22  
23 some advantages in the clinical settings. For example, the automated RPR test reduced the  
24  
25 workload and overall test turn-around time. It also can deal with greater test quantities in a  
26  
27 given time than the manual RPR card test, and does not require test experts. Also, we noticed  
28  
29 that the automated RPR test could be used as a useful monitoring marker of treatment  
30  
31 response, especially if treponemal-specific tests are used for first-line screening of syphilis as  
32  
33 a reverse algorithm of syphilis testing. Recently, this reverse algorithm for syphilis testing has  
34  
35 been suggested and began to adopt because this approach may be more sensitive and effective  
36  
37 than the traditional algorithm<sup>3 4 6</sup> and could be automated. However, the Centers for Disease  
38  
39 Control and Prevention (CDC) still recommend screening for syphilis with a non-treponemal  
40  
41 test first, such as RPR.<sup>2</sup>  
42  
43  
44  
45

46 The automated non-treponemal test has an additional important advantage over the  
47  
48 conventional manual non-treponemal test in addition to those previously described. Our study  
49  
50 presented that the automated RPR test showed earlier seronegative conversion than  
51  
52 conventional card RPR test after syphilis treatment (p=0.004). If we adopt the reverse  
53  
54 algorithm, it could be ideal in that the treponemal tests screen sensitively first and then the  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 non-treponemal tests accurately show negative in treated cases. In this situation we could use  
5  
6 treponemal tests for first-line screening and non-treponemal tests for monitoring the patients  
7  
8 to see seronegative conversion more effectively after treatment.<sup>2 13 14</sup> Unfortunately, our study  
9  
10 had a limited number of syphilitic patients due to low prevalence rate of syphilis in our  
11  
12 country and the number of samples was small and could not be classified according to  
13  
14 syphilis stage. In fact, some late or latent syphilis cases were hard to interpret the results of  
15  
16 non-treponemal test after initial treatment in our study (Case No. 8 or 9 in Table 5). So, further  
17  
18 well designed studies will be needed to clarify the serologic responses of automated RPR  
19  
20 tests after treatment and according to the stage of syphilis infection.  
21  
22

23  
24 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
25  
26 evaluations comparing conventional RPR tests and VDRL tests were reported.<sup>8 15</sup> However,  
27  
28 the results were variable. Tomohiko et al. also suggested that when the automated serological  
29  
30 testing method is used in clinical settings, the same reagent should be consistently selected to  
31  
32 evaluate the changes in antibody titers because the manual serological testing method for  
33  
34 syphilis showed somewhat different results from the automated serological testing methods.<sup>16</sup>  
35  
36 In this study, we noticed moderately consistent results between auto RPR and manual RPR.  
37  
38

39  
40 We found that the automated RPR has a greater processing capability within a limited time  
41  
42 and is more effectively applicable in a reverse syphilis screening algorithm. Through the  
43  
44 reverse syphilis screening algorithm, we could increase the detection sensitivity of syphilis  
45  
46 screening, and the automated RPR test may be useful after treatment for its rapid  
47  
48 seronegative conversion. The automated RPR could be more useful in the treated cases  
49  
50 though it's sensitivity is lower after treatment.  
51

52  
53 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
54  
55 specificity compared to the conventional manual RPR card test. However, the automated  
56  
57



1  
2  
3  
4 RPR test may be more helpful to monitor the seroconversion responses in treated syphilis  
5  
6 patients, especially in the reverse syphilis screening algorithm. Further large-scale studies  
7  
8 including well-categorized patients by syphilis stage are warranted to clarify the accurate  
9  
10 diagnostic efficiency of the automated RPR test.  
11  
12  
13

### 14 **Author affiliations**

15  
16  
17  
18  
19 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

20  
21 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

22  
23 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
24  
25  
26  
27

### 28 **Contributors**

29  
30 Hyon-Suk Kim designed and participated in all the stages of this study. Jong-Han Lee  
31  
32 participated in the experiments and in statistical analyses and draft the manuscript. Chae  
33  
34 Seung Lim and Min-Geol Lee helped to consultations of this study. All authors read and  
35  
36 approved the final manuscript.  
37  
38  
39  
40  
41

### 42 **Funding**

43  
44 None  
45  
46  
47

### 48 **Competing interests**

49  
50 None.  
51  
52  
53  
54

### 55 **Provenance and peer review**

1  
2  
3  
4 Not commissioned; externally peer reviewed.  
5  
6  
7

8 **Data sharing statement**  
9

10 No additional data are available.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## REFERENCES

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep* 2011;60:133-7.
- 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLIS Syphilis Serology Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 4 French P, Gomberg M, Janier M, *et al.* IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin Infect Dis* 2012;25:79-85.
- 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 8 Kim YS, Lee J, Lee HK, *et al.* [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab Med* 2009;29:331-7.
- 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.

- 1  
2  
3  
4 11 Castro RR, Prieto ES, Santo I, *et al.* Evaluation of the passive particle agglutination  
5 test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.  
6  
7  
8 12 Castro R, Prieto ES, Aguas MJ, *et al.* Evaluation of the *Treponema pallidum* particle  
9 agglutination technique (TP.PA) in the diagnosis of neurosyphilis. *J Clin Lab Anal*  
10 2006;20:233-8.  
11  
12  
13 13 Romanowski B, Sutherland R, Fick GH, *et al.* Serologic response to treatment of  
14 infectious syphilis. *Ann Intern Med* 1991;114:1005-9.  
15  
16  
17 14 Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a  
18 paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-  
19 8.  
20  
21  
22 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with  
23 conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.  
24  
25  
26 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the  
27 manual and automated serological testing methods for syphilis. *J Dermatol*  
28 2012;39:355-61.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Licence for Publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.

**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)

Kappa= 0.565

95% confidence interval: 0.422 to 0.709

<sup>1)</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were negative in TPPA test.

<sup>2)</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.

Abbreviations: RPR, rapid plasma regain.

**Table 2** Discrepant RPR results to treponemal test for diagnosis of syphilis

Case No.	Age /Sex	RPR card test	Auto RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 3** Comparison of non-treponemal RPR tests according to *Treponema pallidum* particle agglutination (TPPA) test results

TPPA positive (n=59)				TPPA negative (n=53)			
		HBI HiSens Auto RPR				HBI HiSens Auto RPR	
		Positive	Negative			Positive	Negative
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48
Number of observed agreements: 39 (66.1% of the observations)				Number of observed agreements: 49 (92.5% of the observations)			
Kappa= 0.296				Kappa= 0.293			
95% confidence interval: 0.118 to 0.474				95% confidence interval: -0.212 to 0.798			

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.



**Table 4** Performance characteristics of RPR tests for diagnosis syphilis

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive	31	3
	Negative	28	50
Sensitivity	52.5%	(95% CI: 39.1 % to 65.7 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	91.2%	(95% CI: 76.3 % to 98 %)	
Negative predictive value	64.1%	(95% CI: 52.4 % to 74.7 %)	
	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive	51	3
	Negative	8	50
Sensitivity	86.4%	(95% CI: 75 % to 93.9 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	94.4 %	(95% CI: 84.6 % to 98.8 %)	
Negative predictive value	86.2 %	(95% CI: 74.6 % to 93.8 %)	

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Pretreatment VDRL test value	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	1:8 reactive	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	1:1 weakly reactive	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	1:4 reactive	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	1:1 reactive	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	1:1 weakly reactive	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	1:1 weakly reactive	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	N/A	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	1:1 weakly reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	1:1 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1+	0	1:5120	1:8 reactive	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1:1 reactive	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	1:32 reactive	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	1:1 reactive	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	1:1 reactive	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	1:1 weakly reactive	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	1:2 reactive	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	1:4 reactive	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	1:8 reactive	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	1:8 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	1:16 reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	1:16 reactive	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	1:8 reactive	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	1:16 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination; N/A, not applicable.

1  
2  
3  
4  
5  
6  
7  
8 **Original article**  
9

10  
11 **Comparison of anthe automated rapid plasma reagin (RPR) test toversus the**  
12 **conventional RPR card test in syphilis testing**  
13  
14

15  
16  
17 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>  
18  
19

20  
21 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea  
22

23 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea  
24

25 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
26  
27  
28  
29  
30  
31

32 Correspondence: Hyon-Suk Kim  
33

34 E-mail: kimhs54@yuhs.ac  
35

36 Tel: (+82) 2-2228-2443  
37

38 Fax: (+82) 2-364-1583  
39

40 Department of Laboratory Medicine, Yonsei University College of Medicine  
41

42 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea  
43  
44  
45

46 Running title: Automated RPR test for syphilis testing  
47

48 Number of words: 2,140~~1,903~~; Number of abstract: 274~~262~~  
49

50 0 Figures, 5 Tables, and 16 References  
51  
52  
53  
54

55 | 1  
56  
57  
58  
59  
60

Formatted: Korean

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** Method comparative study using clinical ~~remnant~~ specimens in a single institute

**Participants:** ~~Participants:~~ A total of 112 serum samples including 59 TPPA-~~(*Treponema*~~ ~~(*Treponema*~~ *pallidum* particle agglutination) positive and 53 TPPA-negative specimens were ~~included~~ ~~collected~~ for this evaluation.

Formatted: Font: Italic

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the auto RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed higher seronegative changes (43.5%, 10/23) than the manual RPR card test (4.3%, 1/23) in treated patients after syphilis treatment.

Formatted: Korean

1  
2  
3  
4  
5  
6  
7  
8 **Conclusions:** The automated RPR test showed overall lower sensitivity compared to ~~the~~  
9 manual RPR test based on treponemal test when comparing TPPA, probably due to  
10 ~~but~~  
11 ~~showed~~ higher seronegative conversion after treatment than the conventional RPR card test.  
12  
13 So, the automated RPR test might be more useful to monitor treatment response than  
14 ~~The~~  
15 the conventional RPR card test, especially in the reverse screening algorithm in syphilis  
16 testing test.  
17  
18

19  
20 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement  
21  
22  
23  
24

#### 25 **Strengths and limitations of this study**

- 26  
27  
28 ■ Automated rapid plasma regain (RPR) tests have been introduced in clinical laboratories,  
29 so we compared ~~but variable results were reported when comparing~~ the automated test to  
30 conventional RPR card tests.  
31  
32  
33  
34 ■ The automated RPR ~~test~~ showed overall lower sensitivity compared to the manual RPR  
35 ~~test~~ when comparing to treponemal test, TPPA.  
36  
37  
38 ■ The automated RPR showed higher seronegative conversion after treatment than the  
39 conventional manual RPR. ~~So, the card test.~~ The automated RPR test may be more useful  
40 to monitor treatment response than the conventional manual RPR, especially in the  
41 reverse screening algorithm for syphilis testing. ~~RPR card test.~~  
42  
43  
44  
45  
46  
47 ■ Limitations of this study could ~~should~~ be considered, including ~~its~~ small sample size and  
48 the patient groups could not accurately categorized ~~patients group~~ according to the stage  
49 because of low prevalence of syphilis infection in Korea.  
50  
51  
52  
53  
54



Formatted: List Paragraph, Indent: Left: 0", Hanging: 1.77 ch, First line: -1.77 ch, Bulleted + Level: 1 + Aligned at: 0.28" + Indent at: 0.56"

## INTRODUCTION

Formatted: Font: Not Bold

Formatted: Justified, Space After: 10 pt, Widow/Orphan control, Adjust space between Latin and Asian text, Adjust space between Asian text and numbers

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have decreased, and the prevalence rate is still very low.~~reached a plateau.~~ Even though, ~~Still~~, syphilis is an important ~~infection~~infectious disease because it can cause serious health problems including neurosyphilis and congenital infection. ~~So~~, ~~Therefore~~, appropriate screening, confirmation, and follow-up protocols are~~are~~<sup>2-4</sup> ~~should be~~ well established.<sup>2-4</sup> Serological analysis of non-treponemal reagin tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, ~~and~~ fluorescent treponemal antibody absorption test (FTA-ABS), and Treponema-specific antibody test have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2,5,6</sup> A non-treponemal reagin test is still recommended by the CDC

4

Formatted: Korean

1  
2  
3  
4  
5  
6  
7  
8 to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been  
9  
10 widely used, the VDRL and RPR methods. RPR is the most common first-line non-  
11  
12 treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have  
13  
14 been introduced but variable results were reported when comparing the automated test to  
15  
16 conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the  
17  
18 conventional RPR card test such as greater capacity to deal with large scale samples, minimal  
19  
20 person-to-person variation, simple automated procedures, and rapid reports with good  
21  
22 analytical performances.

23  
24 The aim of this study was to evaluate the possible benefits of an automated RPR test  
25  
26 compared to a conventional RPR card test in clinical application.

## 27 28 29 METHODS

### 30 31 32 Subjects

33  
34 A total of 112 serum samples from 59 syphilis patients (48±21 years-old, year, Male to  
35  
36 Female = 25:34) and 53 non-syphilitic controls (45±17 years-old, year, Male to Female =  
37  
38 27:26) → were collected after treponemal test completed from November 2012 to April 2013  
39  
40 in a university hospital in Korea. Remnant sera from requested treponemal test after  
41  
42 confirmation were included and preserved at -70°C until analysis, analyses. Patients were not  
43  
44 categorized according to the syphilis stage due to the infrequency of syphilis infection. True  
45  
46 syphilis patients were very rare because of its low prevalence in this country. There was a  
47  
48 report that only 1,424 cases are registered in Korean Centers for Control and Prevention  
49  
50 (KCDC) in 2007.-  
51  
52 The automated HiSens Auto RPR test LTIA (HBI Co., Ltd, Anyang, Korea) was compared

1  
2  
3  
4  
5  
6  
7  
8 with ~~manual card~~Macro-Vue RPR ~~Test Card Tests~~ (Becton Dickinson BD Microbiology  
9 Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was performed by a  
10 ~~Treponema pallidum particle agglutination assay (TPPA)~~Serodia-TPPA assay (Fujirebio, Inc.,  
11 ~~Tokyo, Japan~~) according to the manufacturer's instructions. Seroconversion rates of each  
12 non-treponemal RPR tests were evaluated with 23 syphilitic patients who had medical  
13 ~~history~~histories of syphilis treatment.  
14  
15  
16  
17  
18  
19

## 20 Serologic tests

### 21 Conventional RPR card test

22  
23 ~~The~~Briefly, the principle of the conventional manual RPR card test is as follows: the Macro-  
24 Vue RPR Card test (~~Becton Dickinson BD Microbiology Systems, Sparks, MD, USA~~) uses  
25 cardiophilin antigen with a carbon particle to detect ~~reagin, reagin, an antibody-like substance~~  
26 ~~present in the serum or plasma of syphilis patients~~. Reagin binds to the test antigen, which  
27 consists of cardiophilin-lecithin-cholesterol particles, causing macroscopic flocculation.  
28 Controls were established in each ~~day's~~ testing to confirm optimal reactivity of the antigen.  
29 ~~The~~Each step of the test procedure was followed according to the manufacturer's instructions.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 Automated RPR

41  
42 HiSens Auto RPR LTIA (~~HBI Co., Ltd, Anyang, Korea~~) is a latex turbidimetric  
43 immunoassay using latex particles coated with lecithin and cardiophilin. The latex particle  
44 reacts with the reagin in the serum of syphilis patients. ~~The~~ 15- $\mu$ L serum samples were  
45 ~~reacted with~~used for analysis and then 120  $\mu$ L Hisens auto RPR LTIA R1 (buffer) and 60  $\mu$ L  
46 Hisens auto RPR LTIA R2 (latex reagent containing cardiophilin-lecithin-cholesterol 1.0  
47 mg/mL) ~~in~~ CA-400 autoanalyzer (~~Furuno Electric Co., Ltd, Nishinomiya, Japan~~). The CA-  
48  
49  
50  
51  
52  
53  
54



1  
2  
3  
4  
5  
6  
7  
8 400 photometric analyzer was used for the automated procedure and analysis. The  
9 absorbance were reacted within 10 seconds. The absorption of reaction at 600 nm was read  
10 after 5.3 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens  
11 auto RPR ~~that were~~ equal to or greater than 1.0 RPR unit (R.U.) were considered as indicated  
12 a reactive RPR. The upper detection limit result to syphilis. A CA-400 (Furuno Electric Co.,  
13 Ltd. Nishinomiya, Japan) photometric analyzer was 20 R.U., used for the automated  
14 procedure and analysis.

### 21 22 23 ***Treponema pallidum* particle agglutination (TPPA)**

24 The Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) is based on the agglutination of  
25 colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain)  
26 antigen. For each specimen, a 100- $\mu$ L sample of diluent and 25  $\mu$ L of test specimen were  
27 mixed first ~~and, then~~ 2-fold serial dilutions were made with 25  $\mu$ L of sample diluent. The ~~3rd~~  
28 ~~well of the test plate was mixed with unsensitized particles, while~~ sensitized particles ~~from~~  
29 ~~4th well~~ were serially mixed in the next wells with a plate mixer for 30 seconds. After ~~a 2~~  
30 ~~hours-hour~~ incubation at room temperature, the result of the agglutination assay was read.  
31 The Serodia TPPA assay results were interpreted ~~by to compare~~ the agglutination patterns with  
32 of reagents and positive and negative controls. ~~Sensitized particles (1:80 final dilution or~~  
33 ~~greater) were considered to indicate a positive reaction. For quantitative results, the antibody~~  
34 ~~titer was determined as being the final dilution showing a positive pattern.~~

### 35 36 37 38 39 40 41 42 43 44 45 46 47 48 **Statistical analyses**

49 The percent agreement, kappa coefficient, ~~of between~~ automated RPR test with and manual  
50 RPR card test was calculated. The overall sensitivity and specificity of each test were

1  
2  
3  
4  
5  
6  
7  
8 calculated based on the data from TPPA results. Kappa values were used to categorize results  
9 as very good (0.81 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or  
10 poor (0 to 0.2).<sup>9</sup> The McNemar test was used to compare the seroconversion rate between the  
11 automated RPR test and the conventional manual RPR card test and was performed by ~~IBM-~~  
12 SPSS Statistics Version 20 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was  
13 considered ~~as~~ statistically significant.  
14  
15  
16  
17  
18  
19

## 20 RESULTS

21  
22  
23  
24  
25 The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709,  
26 Table 1). The strength of agreement between the automated RPR test and manual RPR card  
27 test was considered to be “moderate” according to the kappa value scale. The specimens of  
28 both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR  
29 negative results (n=56) showed 85.7% (48/56) TPPA-negative results.  
30  
31  
32  
33

34 There were 24 discrepant results (21.4%) between the two ~~kinds of~~ RPR tests, including 22  
35 negative cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the  
36 BD Macro-Vue RPR card test. And there were two false positive cases in HiSens Auto RPR  
37 LTIA test. Of these 22 discrepant results, 20 cases were TPPA-positive and 2 cases were  
38 TPPA-negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA test but  
39 negative in the BD Macro-Vue RPR card test. These 2 cases were negative in the TPPA test.  
40  
41  
42  
43  
44  
45

46 There were 4 results with discrepancies between both of the RPR tests and the TPPA assay  
47 which were due to conditions other than syphilis infections (Table 2). The strength of  
48 agreement between the auto RPR and manual RPR card tests was “fair” (kappa value: 0.296,  
49 (59 TPPA positive ~~results; results~~); 0.293, (53 TPPA negative results)) according to TPPA  
50  
51  
52  
53  
54

1  
2  
3  
4  
5  
6  
7  
8 results (Table 3).

9  
10 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
11 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively.

12  
13 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
14 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
15 gave a higher seronegative conversion rate after syphilis treatment, with a value of 43.5%  
16 (10/23), than that of the conventional RPR card test, which was 4.3% (1/23,  $p=0.004$ ) by  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
McNemar test. Detailed comparison results of treated syphilis cases are described in Table 5.

## DISCUSSION

Manual RPR test has been used for decades, and recently the automated RPR test method was launched and has been used because of its convenience in clinical settings. However, there has been the need to thorough inspection and comparing results of this new automated test to conventional manual RPR test in the diagnostic approaches. The treponemal test results will not change even after treatment, and the patients live with positive results for the remainder of their lives regardless of treatment or disease activity.

Treponemal tests cannot discriminate between the past infections, active disease, treated patients, and non-treated patients.<sup>10</sup> ~~Patients who are treponemal test reactive have positive results for this test for the remainder of their lives, regardless of treatment or disease activity.~~<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have been treated during the primary or secondary stage of the disease. When the primary or secondary stage of a first *T. pallidum* infection is treated, nontreponemal test ~~Usually, the titer should show~~<sup>7</sup> showed a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> ~~treatment.~~<sup>7</sup> Therefore, ~~a guaranteed~~ non-treponemal test is important for managing the clinical settings to

1  
2  
3  
4  
5  
6  
7  
8 ~~manage~~ syphilitic patients.

9  
10 We compared an automated RPR test with a conventional RPR card test in ~~the confirmed~~  
11 ~~patients' sera with~~ ~~eluding a~~ TPPA ~~test~~. The TPPA test was reported to be as sensitive as the  
12 FTA-ABS test in ~~all the stages of primary~~-syphilis and as useful as the RPR test for  
13 monitoring therapy. The TPPA test is also ~~known to be~~ less subjective than the FTA-ABS and  
14 easier to read than the microhemagglutination assay for antibodies to *Treponema pallidum*  
15 (MHA-TP).<sup>11</sup> TPPA has also been suggested to be applied ~~to in~~-CSF ~~samples~~ to diagnose  
16 neurosyphilis.<sup>12</sup>

17  
18  
19  
20  
21  
22  
23 ~~In our study, Although~~ the BD Macro-Vue RPR card test showed a better ~~sensitivity~~ ~~positivity~~  
24 than did the HBI HiSens Auto RPR LTIA test in syphilis ~~screening~~. ~~But, screening~~, the  
25 automated RPR test does have some advantages in the clinical settings. For example, the  
26 automated RPR test reduced the workload and overall test turn-around time. It also can deal  
27 with greater test quantities in a given time than the manual RPR card test, and does not  
28 require test experts. Also, we noticed that the automated RPR test ~~could~~ ~~may~~ be ~~used as a~~  
29 useful ~~for~~ monitoring ~~marker of~~ treatment response, especially if treponemal-specific tests are  
30 used for first-line ~~screening~~ ~~detection~~ of syphilis as a reverse algorithm of syphilis  
31 ~~testing~~ ~~screening~~. Recently, this reverse algorithm for syphilis ~~testing~~ ~~screening~~ has been  
32 suggested ~~and began to adopt as a first line screening for syphilis~~ because this approach may  
33 be more sensitive and effective than the traditional algorithm<sup>3 4 6</sup> and could be automated.

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44 However, the Centers for Disease Control and Prevention (CDC) still recommend screening  
45 for syphilis with a non-treponemal test first, such as RPR.<sup>2</sup>

46  
47  
48 The automated non-treponemal test has an additional important advantage over the  
49 conventional manual non-treponemal test in addition to those previously described. Our study  
50 presented that the automated RPR test showed earlier seronegative conversion than  
51  
52  
53

1  
2  
3  
4  
5  
6  
7  
8 conventional card RPR test ~~in discrimination~~ after syphilis treatment ( $p=0.004$ ). If we adopt  
9 the reverse algorithm, it could be ideal in that the treponemal tests screen sensitively first and  
10 then the non-treponemal tests accurately show negative in ~~the~~ treated cases. In this situation  
11 we could use treponemal tests for first-line screening and non-treponemal tests for monitoring  
12 the patients to see seronegative conversion more effectively after treatment.<sup>2 13 14</sup>

13  
14  
15  
16  
17 Unfortunately, ~~our~~ this study had a limited number of ~~syphiliticsyphilitic~~ patients due to low  
18 prevalence rate of syphilis ~~in our country~~ and ~~the number of samples was small and could not~~  
19 been classified ~~according to as each~~ syphilis stage. ~~In fact, some late or latent syphilis cases~~  
20 ~~were hard to interpret the results of non-treponemal test after initial treatment in our study.~~  
21 ~~(Case No. 8 or 9 in Table 5). So, further- Further,~~ well designed studies will be needed to  
22 clarify the serologic responses of automated RPR tests after treatment and according to the  
23 stage of syphilis infection.

24  
25  
26  
27  
28  
29  
30 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
31 ~~some~~ evaluations comparing ~~conventional~~ RPR tests ~~and to~~ VDRL tests were reported.<sup>8 15</sup>

32  
33  
34 However, the results were variable. Tomohiko et al. also suggested that when the automated  
35 serological testing method is used in clinical settings, the same reagent should be consistently  
36 selected to evaluate the changes in antibody titers because the manual serological testing  
37 method for syphilis showed somewhat different results from ~~those of~~ the automated  
38 serological testing methods.<sup>16</sup> In ~~this the current~~ study, we ~~noticed also noted~~ moderately  
39 consistent results between auto RPR and manual RPR.

40  
41  
42  
43  
44  
45  
46 We found that the automated RPR has a greater processing capability within a limited time  
47 and is more effectively applicable in a reverse syphilis screening algorithm. Through the  
48 reverse syphilis screening algorithm, we could increase the detection sensitivity of syphilis  
49 screening, and the ~~relatively low sensitivity of the~~ automated RPR test may be ~~useful after~~

1  
2  
3  
4  
5  
6  
7  
8 treatment compensated for by its rapid seronegative conversion. The automated RPR could be  
9 more useful in the treated cases though it's sensitivity is lower after treatment.

10  
11 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
12 specificity compared to the conventional manual RPR card test. However, the automated  
13 RPR test may be more helpful to monitor the seroconversion responses in treated syphilis  
14 patients, treatment, especially in the reverse syphilis screening algorithm. Further large-scale  
15 studies including patients well-categorized patients by syphilis stage are warranted to clarify  
16 the accurate diagnostic efficiency of the automated RPR test.  
17  
18  
19  
20  
21  
22  
23

#### 24 **Author affiliations**

25  
26  
27  
28 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

29 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

30 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
31  
32  
33  
34

#### 35 **Contributors**

36  
37 Hyon-Suk Kim designed and participated in all the stages of this the study. Jong-Han Lee  
38 participated in the experiments and in statistical analyses and draft the manuscript. Chae  
39 Seung Lim and Min-Geol Lee helped to consultations of this study. All authors read and  
40 approved the final manuscript.  
41  
42  
43  
44  
45  
46  
47

#### 48 **Funding**

49 None  
50  
51  
52  
53  
54

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Competing interests**

None.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

No additional data are available.

For peer review only

Formatted: Korean

13

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
**REFERENCES**

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep* 2011;60:133-7.
- 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLS Syphilis Serology Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 4 French P, Gomberg M, Janier M, *et al.* IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin Infect Dis* 2012;25:79-85.
- 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 8 Kim YS, Lee J, Lee HK, *et al.* [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab Med* 2009;29:331-7.



- 1  
2  
3  
4  
5  
6  
7  
8 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 9  
10  
11 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
- 12  
13  
14  
15 11 Castro RR, Prieto ES, Santo I, *et al.* Evaluation of the passive particle agglutination test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.
- 16  
17  
18  
19 12 Castro R, Prieto ES, Aguas MJ, *et al.* Evaluation of the *Treponema pallidum* particle agglutination technique (TP.PA) in the diagnosis of neurosyphilis. *J Clin Lab Anal* 2006;20:233-8.
- 20  
21  
22  
23  
24  
25 13 Romanowski B, Sutherland R, Fick GH, *et al.* Serologic response to treatment of infectious syphilis. *Ann Intern Med* 1991;114:1005-9.
- 26  
27  
28  
29 14 Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-8.
- 30  
31  
32  
33  
34  
35 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.
- 36  
37  
38  
39 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the manual and automated serological testing methods for syphilis. *J Dermatol* 2012;39:355-61.
- 40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Font: Italic, Check spelling and grammar

Formatted: Font: Italic, Check spelling and grammar

Formatted: Korean

15

### Licence for Publication statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.

Formatted: Korean

16

**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)

Kappa= 0.565

95% confidence interval: 0.422 to 0.709

<sup>1)</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were negative in TPPA test.

<sup>2)</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.

Abbreviations: RPR, rapid plasma regain.

**Table 2** ~~Discrepant RPR~~Summary of the four patients showing discrepant results to treponemal test ~~for diagnosis of syphilis~~

Case No.	Age /Sex	RPR card test	Auto RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

Formatted Table

Formatted: Korean

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Table 3** Comparison of non-treponemal RPR tests according to *Treponema pallidum* particle agglutination (TPPA) test results

TPPA positive (n=59)	HBI HiSens Auto RPR		TPPA negative (n=53)	HBI HiSens Auto RPR			
	Positive	Negative		Positive	Negative		
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48

Number of observed agreements: 39 (66.1% of the observations)      Number of observed agreements: 49 (92.5% of the observations)  
Kappa= 0.296      Kappa= 0.293  
95% confidence interval: 0.118 to 0.474      95% confidence interval: -0.212 to 0.798

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

Formatted: Font: Italic

Formatted: Font: Italic

19

Formatted: Korean

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 4** Performance characteristics Overall Results of non-treponemal RPR tests for diagnosis syphilis

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive	31	3
	Negative	28	50
Sensitivity	52.5%	(95% CI: 39.1 % to 65.7 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	91.2%	(95% CI: 76.3 % to 98 %)	
Negative predictive value	64.1%	(95% CI: 52.4 % to 74.7 %)	
BD Macro-Vue RPR card	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive	51	3
	Negative	8	50
Sensitivity	86.4%	(95% CI: 75 % to 93.9 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	94.4 %	(95% CI: 84.6 % to 98.8 %)	
Negative predictive value	86.2 %	(95% CI: 74.6 % to 93.8 %)	

Formatted Table

Abbreviations: RPR, rapid plasma regain; TPPA, Treponema pallidum particle agglutination.


Formatted: Font: Times New Roman, 12 pt

Formatted: Line spacing: 1.5 lines

Formatted: Korean

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



|

21

Formatted: Korean

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Pretreatment VDRL test value	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	1:8 reactive	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	1:1 weakly reactive	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	1:4 reactive	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	1:1 reactive	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	1:1 weakly reactive	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	1:1 weakly reactive	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	N/A	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	1:1 weakly reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	1:1 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1+	0	1:5120	1:8 reactive	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1:1 reactive	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	1:32 reactive	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	1:1 reactive	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	1:1 reactive	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	1:1 weakly reactive	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	1:2 reactive	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	1:4 reactive	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	1:8 reactive	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	1:8 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	1:16 reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	1:16 reactive	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	1:8 reactive	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	1:16 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

**Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination;**

**N/A, not applicable.**

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1	0	1:5120	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

|



**Formatted:** Font: Times New Roman, 16 pt

**Formatted:** Line spacing: Double

For peer review only

**STARD checklist for reporting of studies of diagnostic accuracy**  
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	4
<b>METHODS</b>			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	5
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	5
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	5
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	5
<i>Test methods</i>	7	The reference standard and its rationale.	6
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	5-6
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	5-6
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	N/A
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	5-6
	13	Methods for calculating test reproducibility, if done.	N/A
<b>RESULTS</b>			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	5
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	5
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	N/A
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	N/A
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	7
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	7
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	8-10

# BMJ Open

## Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR card test in syphilis testing

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005664.R2
Article Type:	Research
Date Submitted by the Author:	02-Oct-2014
Complete List of Authors:	Lee, Jong-Han; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lim, Chae Seung; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lee, Min-Geol; Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea, Kim, Hyon-Suk; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Infectious diseases, Diagnostics
Keywords:	Public health < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES, IMMUNOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Original article**  
5  
6  
7

8 **Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR**  
9 **card test in syphilis testing**  
10  
11

12  
13  
14  
15 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>  
16  
17

18  
19  
20 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

21  
22 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

23  
24 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
25  
26  
27  
28  
29  
30  
31  
32

33 Correspondence: Hyon-Suk Kim

34 E-mail: kimhs54@yuhs.ac

35  
36  
37 Tel: (+82) 2-2228-2443

38  
39 Fax: (+82) 2-364-1583

40  
41  
42 Department of Laboratory Medicine, Yonsei University College of Medicine

43  
44 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea  
45  
46  
47

48 Running title: Automated RPR test for syphilis testing

49  
50 Number of words: 2,117; Number of abstract: 270

51  
52  
53 0 Figures, 5 Tables, and 16 References  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** A comparative study of lab methods using clinical specimens in a single institute.

**Participants:** A total of 112 serum samples including 59 TPPA- (*Treponema pallidum* particle agglutination) positive and 53 TPPA-negative specimens were included for this evaluation.

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the automated RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed more seroconversion changes (43.5%, 10/23) than the manual RPR card test (4.3%, 1/23) in treated patients.

**Conclusions:** The automated RPR test showed overall lower sensitivity compared to conventional RPR test based on treponemal test. But, the automated RPR test showed more seroconversion after treatment than the conventional RPR card test. The automated RPR test

1  
2  
3  
4 might be used to monitor treatment response, especially in the reverse screening algorithm in  
5  
6 syphilis testing.  
7  
8

9 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement  
10  
11

### 12 **Strengths and limitations of this study** 13 14

- 15  
16  
17  
18 ■ Automated rapid plasma regain (RPR) tests have been introduced in clinical laboratories,  
19  
20 so we compared the automated test to conventional RPR card tests.  
21  
22
- 23  
24 ■ The automated RPR showed overall lower sensitivity compared to the conventional RPR  
25  
26 when comparing to treponemal test, TPPA.  
27  
28
- 29  
30 ■ The automated RPR showed higher seroconversion after treatment than the conventional  
31  
32 manual RPR. So, the automated RPR test may be used to monitor treatment response,  
33  
34 especially in the reverse screening algorithm for syphilis testing.  
35  
36
- 37  
38 ■ Limitations of this study could be considered, including small sample size and the patient  
39  
40 groups could not accurately categorized according to the stage because of low prevalence  
41  
42 of syphilis in Korea.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have decreased, and the prevalence rate is still very low.<sup>1</sup> Despite these low rates, syphilis is an important infection because it can cause serious health problems including neurosyphilis and congenital infection. So, appropriate screening, confirmation, and follow-up protocols are well established.<sup>2-4</sup> Serological analysis of non-treponemal reagent tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, fluorescent treponemal antibody absorption test (FTA-ABS) and Treponema-specific antibody test have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2,5,6</sup> A non-treponemal reagent test is still recommended by the CDC to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been widely used, the VDRL and RPR methods. RPR is the most common first-line non-treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have been introduced but variable results were reported when comparing the automated test to conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the conventional RPR card test such as greater capacity to deal with a large number of samples, minimal person-to-person variation, and simple automated procedures.

The aim of this study was to evaluate the possible benefits of an automated RPR test

1  
2  
3  
4 compared to a conventional RPR card test in clinical application.  
5  
6  
7

## 8 **METHODS**

### 9 **Subjects**

10  
11  
12  
13  
14  
15 A total of 112 serum samples from 59 syphilis patients ( $48\pm 21$  years-old, Male to Female =  
16  
17 25:34, ratio = 0.7) and 53 non-syphilitic controls ( $45\pm 17$  years-old, Male to Female = 27:26,  
18  
19 ratio = 1) after treponemal test were collected from November 2012 to April 2013 in a  
20  
21 university hospital in Korea. Remnant sera from requested treponemal test after confirmation  
22  
23 were included and preserved at  $-70^{\circ}\text{C}$  until analysis. Patients were not categorized according  
24  
25 to the syphilis stage due to the infrequency of syphilis infection. True syphilis patients were  
26  
27 very rare because of its low prevalence in this country. There was a report that only 1,424  
28  
29 cases are registered in Korean Centers for Control and Prevention (KCDC) in 2007.  
30  
31

32  
33 The automated RPR test was compared with manual card RPR Test (Becton Dickinson BD  
34  
35 Microbiology Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was  
36  
37 performed by a *Treponema pallidum* particle agglutination assay (TPPA) according to the  
38  
39 manufacturer's instructions. Seroconversion rates of each non-treponemal RPR tests were  
40  
41 evaluated with 23 syphilitic patients who had medical history of syphilis treatment.  
42  
43  
44  
45

### 46 **Serologic tests**

#### 47 **Conventional RPR card test**

48  
49  
50  
51 The Macro-Vue RPR Card test (Becton Dickinson BD Microbiology Systems, Sparks, MD,  
52  
53 USA) uses cardiolipin antigen with a carbon particle to detect reagin. Reagin binds to the test  
54  
55 antigen, which consists of cardiolipin-lecithin-cholesterol particles, causing macroscopic  
56  
57  
58  
59  
60



1  
2  
3  
4 flocculation. Controls were established in each testing to confirm optimal reactivity of the  
5 antigen. The test procedure was followed according to the manufacturer's instructions.  
6  
7  
8  
9

### 10 **Automated RPR**

11  
12 HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) is a latex turbidimetric  
13 immunoassay using latex particles coated with lecithin and cardiolipin. The latex particle  
14 reacts with the reagin in the serum of syphilis patients. The 15 µL serum samples were  
15 reacted with 120 µL Hisens auto RPR LTIA R1 (buffer) and 60 µL Hisens auto RPR LTIA R2  
16 (latex reagent containing cardiolipin-lecithin-cholesterol 1.0 mg/mL) in CA-400 autoanalyzer  
17 (Furuno Electric Co., Ltd. Nishinomiya, Japan). The CA-400 photometric analyzer was used  
18 for the automated procedure and analysis. The absorbance at 600 nm was read after 5.3  
19 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens auto RPR  
20 equal to or greater than 1.0 RPR unit (R.U.) were considered as reactive RPR. The upper  
21 detection limit was 20 R.U..  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 ***Treponema pallidum* particle agglutination (TPPA)**

38  
39 The Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) is based on the agglutination of  
40 colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain)  
41 antigen. For each specimen, a 100 µL sample of diluent and 25 µL of test specimen were  
42 mixed first and 2-fold serial dilutions were made with 25 µL of sample diluent. The sensitized  
43 particles were serially mixed in the next wells with a plate mixer for 30 seconds. After 2  
44 hours of incubation at room temperature, the result of the agglutination assay was read. The  
45 Serodia TPPA assay results were interpreted by the agglutination patterns with positive and  
46 negative controls.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Statistical analyses

The percent agreement, kappa coefficient, of automated RPR test with manual RPR card test was calculated. The overall sensitivity and specificity of each test were calculated based on the data from TPPA results. Kappa values were used to categorize results as very good (0.81 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or poor (0 to 0.2).<sup>9</sup> The McNemar test was used to compare the seroconversion rate between the automated RPR test and the conventional manual RPR card test and was performed by SPSS Statistics Version 20 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was considered statistically significant.

## RESULTS

The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709, Table 1). The strength of agreement between the automated RPR test and manual RPR card test was considered to be “moderate” according to the kappa value scale. The specimens of both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR negative results (n=56) showed 85.7% (48/56) TPPA-negative results.

There were 24 discrepant results (21.4%) between the two RPR tests, including 22 negative cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the BD Macro-Vue RPR card test. Of these 22 discrepant results, 20 cases were TPPA-positive and 2 cases were TPPA-negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA test but negative in the BD Macro-Vue RPR card test. These 2 cases were negative in the TPPA test. There were 4 results with discrepancies between both of the RPR tests and the

1  
2  
3  
4 TPPA assay which were due to conditions other than syphilis infections (Table 2). The  
5  
6 strength of agreement between the automated RPR and manual RPR card tests was “fair”  
7  
8 (kappa value: 0.296, 59 TPPA positive results; 0.293, 53 TPPA negative results) according to  
9  
10 TPPA results (Table 3).

11  
12 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
13  
14 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively.  
15  
16 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
17  
18 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
19  
20 gave a higher seroconversion rate after syphilis treatment, with a value of 43.5% (10/23),  
21  
22 than that of the conventional RPR card test, which was 4.3% (1/23,  $p=0.004$ ) by McNemar  
23  
24 test. Detailed comparison results of treated syphilis cases are described in Table 5.  
25  
26  
27  
28  
29

## 30 31 **DISCUSSION**

32  
33 Manual RPR test has been used for decades, and recently the automated RPR test method  
34  
35 was launched and has been used because of its convenience in clinical settings. However,  
36  
37 there has been the need to thorough inspection and comparing results of this new automated  
38  
39 test to conventional manual RPR test in the diagnostic approaches. The treponemal test  
40  
41 results will not change even after treatment, and the patients live with positive results for the  
42  
43 remainder of their lives regardless of treatment or disease activity. Treponemal tests cannot  
44  
45 discriminate between past infections, active disease, treated patients, and non-treated  
46  
47 patients.<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have  
48  
49 been treated during the primary or secondary stage of the disease. When the primary or  
50  
51 secondary stage of a first *T. pallidum* infection is treated, nontreponemal test titer should  
52  
53 show a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> Therefore, non-  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 treponemal test is important for managing syphilitic patients.

5  
6 We compared an automated RPR test with a conventional RPR card test in the sera confirmed  
7  
8 by TPPA. The TPPA test is also known to be less subjective than the FTA-ABS and easier to  
9  
10 read than the microhemagglutination assay for antibodies to *Treponema pallidum* (MHA-  
11  
12 TP).<sup>11</sup> TPPA has also been suggested to be applied to CSF samples to diagnose  
13  
14 neurosyphilis.<sup>12</sup>

15  
16  
17 In our study, the conventional BD Macro-Vue RPR card test showed better sensitivity than  
18  
19 did the HBI HiSens Auto RPR LTIA test in syphilis screening. Though, the automated RPR  
20  
21 test does have some advantages in the clinical settings. For example, the automated RPR  
22  
23 test reduced the workload and overall test turn-around time. It also can deal with greater test  
24  
25 quantities in a given time than the manual RPR card test, and does not require test experts.  
26  
27 Also, we noticed that the automated RPR test could be used as a monitoring marker of  
28  
29 treatment response, especially if treponemal tests are used for first-line screening of syphilis  
30  
31 as a reverse algorithm of syphilis testing. Recently, this reverse algorithm for syphilis testing  
32  
33 has been suggested and has been adopted in many jurisdictions because this approach may be  
34  
35 more sensitive and effective than the traditional algorithm<sup>3 4 6</sup> in a low prevalence area and  
36  
37 could be automated. However, the Centers for Disease Control and Prevention (CDC) still  
38  
39 recommend screening for syphilis with a non-treponemal test first, such as RPR.<sup>2</sup>

40  
41  
42 Our study presented that the automated RPR test showed earlier seroconversion than  
43  
44 conventional card RPR test after syphilis treatment ( $p=0.004$ ). If we adopt the reverse  
45  
46 algorithm, it could be used that the treponemal tests screen sensitively first and then the non-  
47  
48 treponemal tests accurately show negative change in treated cases. In this situation we could  
49  
50 use treponemal tests for first-line screening and non-treponemal tests for monitoring the  
51  
52 patients to see seroconversion more effectively after treatment.<sup>2 13 14</sup> Unfortunately, our study  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 had a limited number of syphilitic patients due to low prevalence rate of syphilis in our  
5  
6 country and the number of samples was small and could not be classified according to  
7  
8 syphilis stage. In fact, some late or latent syphilis cases were hard to interpret the results of  
9  
10 non-treponemal test after initial treatment in our study (Case No. 8 or 9 in Table 5). So, further  
11  
12 well designed studies will be needed to clarify the serologic responses of automated RPR  
13  
14 tests after treatment and according to the stage of syphilis infection.

15  
16  
17 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
18  
19 evaluations comparing conventional RPR tests and VDRL tests were reported.<sup>8 15</sup> However,  
20  
21 the results were variable. Tomohiko et al. also suggested that when the automated serological  
22  
23 testing method is used in clinical settings, the same reagent should be consistently selected to  
24  
25 evaluate the changes in antibody titers because the manual serological testing method for  
26  
27 syphilis showed somewhat different results from the automated serological testing methods.<sup>16</sup>  
28  
29 In this study, we noticed moderately consistent results between automated RPR and manual  
30  
31 RPR.  
32  
33

34  
35 We found that the automated RPR has a greater processing capability within a limited time  
36  
37 and is effectively applicable. Through the reverse syphilis screening algorithm, we can  
38  
39 increase the detection sensitivity of syphilis screening by treponemal test screening initially  
40  
41 and the automated RPR test may be used after treatment for its rapid seroconversion, though  
42  
43 the sensitivity of automated RPR is lower than manual RPR.  
44  
45

46  
47 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
48  
49 specificity compared to the conventional manual RPR card test. Therefore, we thought that  
50  
51 automated RPR is not matched to use as initial screening of syphilis. However, the automated  
52  
53 RPR seems to be earlier seroconversion response in treated cases than those of conventional  
54  
55 RPR card test. If reverse algorithm is applied, sensitive treponemal tests were used in first  
56  
57  
58  
59  
60

1  
2  
3  
4 line, and then the automated RPR might be used as adjunct to detect earlier seroconversion in  
5  
6 treated patients.  
7

8  
9 Further large-scale studies including well-categorized patients by syphilis stage are  
10  
11 warranted to clarify the accurate diagnostic efficiency of the automated RPR test.  
12  
13

### 14 15 **Author affiliations**

16  
17  
18  
19 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea  
20

21 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea  
22

23 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
24  
25  
26  
27

### 28 29 **Contributors**

30 Hyon-Suk Kim designed and participated in all the stages of this study. Jong-Han Lee  
31  
32 participated in the experiments and in statistical analyses and draft the manuscript. Chae  
33  
34 Seung Lim and Min-Geol Lee helped to consultations of this study. All authors read and  
35  
36 approved the final manuscript.  
37  
38  
39  
40  
41  
42  
43

### 44 45 **Funding**

46 None  
47  
48  
49

### 50 51 **Competing interests**

52 None.  
53  
54  
55  
56  
57  
58  
59  
60

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

No additional data are available.

No data sharing

For peer review only

## REFERENCES

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep* 2011;60:133-7.
- 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLS Syphilis Serology Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 4 French P, Gomberg M, Janier M, *et al.* IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin Infect Dis* 2012;25:79-85.
- 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 8 Kim YS, Lee J, Lee HK, *et al.* [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab Med* 2009;29:331-7.
- 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
- 11 Castro RR, Prieto ES, Santo I, *et al.* Evaluation of the passive particle agglutination



- 1  
2  
3  
4 test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.  
5  
6 12 Castro R, Prieto ES, Aguas MJ, *et al.* Evaluation of the *Treponema pallidum* particle  
7 agglutination technique (TP.PA) in the diagnosis of neurosyphilis. *J Clin Lab Anal*  
8 2006;20:233-8.  
9  
10  
11  
12 13 Romanowski B, Sutherland R, Fick GH, *et al.* Serologic response to treatment of  
14 infectious syphilis. *Ann Intern Med* 1991;114:1005-9.  
15  
16  
17 14 Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a  
18 paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-  
19 8.  
20  
21  
22  
23 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with  
24 conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.  
25  
26  
27  
28 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the  
29 manual and automated serological testing methods for syphilis. *J Dermatol*  
30 2012;39:355-61.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Licence for Publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.

**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)

Kappa= 0.565

95% confidence interval: 0.422 to 0.709

<sup>1)</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were negative in TPPA test.

<sup>2)</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.

Abbreviations: RPR, rapid plasma reagin.

**Table 2** Discrepant RPR results to treponemal test for diagnosis of syphilis

Case No.	Age /Sex	RPR card test	Automated RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 3** Comparison of non-treponemal RPR tests according to *Treponema pallidum* particle agglutination (TPPA) test results

TPPA positive (n=59)				TPPA negative (n=53)			
		HBI HiSens Auto RPR				HBI HiSens Auto RPR	
		Positive	Negative			Positive	Negative
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48
Number of observed agreements: 39 (66.1% of the observations)				Number of observed agreements: 49 (92.5% of the observations)			
Kappa= 0.296				Kappa= 0.293			
95% confidence interval: 0.118 to 0.474				95% confidence interval: -0.212 to 0.798			

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 4** Performance characteristics of RPR tests for diagnosis syphilis

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive	31	3
	Negative	28	50
Sensitivity	52.5%	(95% CI: 39.1 % to 65.7 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	91.2%	(95% CI: 76.3 % to 98 %)	
Negative predictive value	64.1%	(95% CI: 52.4 % to 74.7 %)	
	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive	51	3
	Negative	8	50
Sensitivity	86.4%	(95% CI: 75 % to 93.9 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	94.4 %	(95% CI: 84.6 % to 98.8 %)	
Negative predictive value	86.2 %	(95% CI: 74.6 % to 93.8 %)	

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Pretreatment VDRL test value	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	1:8 reactive	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	1:1 weakly reactive	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	1:4 reactive	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	1:1 reactive	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	1:1 weakly reactive	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	1:1 weakly reactive	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	N/A	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	1:1 weakly reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	1:1 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1+	0	1:5120	1:8 reactive	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1:1 reactive	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	1:32 reactive	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	1:1 reactive	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	1:1 reactive	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	1:1 weakly reactive	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	1:2 reactive	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	1:4 reactive	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	1:8 reactive	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	1:8 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	1:16 reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	1:16 reactive	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	1:8 reactive	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	1:16 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination; N/A, not applicable.

**STARD checklist for reporting of studies of diagnostic accuracy**  
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	4
<b>METHODS</b>			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	5
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	5
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	5
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	5
<i>Test methods</i>	7	The reference standard and its rationale.	6
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	5-6
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	5-6
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	N/A
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	5-6
	13	Methods for calculating test reproducibility, if done.	N/A
<b>RESULTS</b>			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	5
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	5
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	N/A
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	N/A
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	7
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	7
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	8-10



# BMJ Open

## Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR card test in syphilis testing

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005664.R3
Article Type:	Research
Date Submitted by the Author:	08-Oct-2014
Complete List of Authors:	Lee, Jong-Han; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lim, Chae Seung; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lee, Min-Geol; Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea, Kim, Hyon-Suk; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Infectious diseases, Diagnostics
Keywords:	Public health < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES, IMMUNOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Original article**  
5  
6  
7

8 **Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR**  
9 **card test in syphilis testing**  
10  
11

12  
13  
14  
15 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>  
16  
17

18  
19  
20 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

21 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

22 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Correspondence: Hyon-Suk Kim

34 E-mail: kimhs54@yuhs.ac

35  
36  
37 Tel: (+82) 2-2228-2443

38  
39 Fax: (+82) 2-364-1583

40  
41  
42 Department of Laboratory Medicine, Yonsei University College of Medicine

43  
44 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea  
45  
46  
47

48 Running title: Automated RPR test for syphilis testing

49  
50 Number of words: 2,117; Number of abstract: 270

51  
52  
53 0 Figures, 5 Tables, and 16 References  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** A comparative study of lab methods using clinical specimens in a single institute.

**Participants:** A total of 112 serum samples including 59 TPPA-(*Treponema pallidum* particle agglutination) positive and 53 TPPA-negative specimens were included for this evaluation.

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the automated RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed more seroconversion changes (43.5%, 10/23) than the manual RPR card test (4.3%, 1/23) in treated patients.

**Conclusions:** The automated RPR test showed overall lower sensitivity compared to conventional RPR test based on treponemal test. But, the automated RPR test showed more seroconversion after treatment than the conventional RPR card test. The automated RPR test

1  
2  
3  
4 might be used to monitor treatment response, especially in the reverse screening algorithm in  
5  
6 syphilis testing.  
7  
8

9 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement  
10  
11

### 12 **Strengths and limitations of this study**

13  
14

- 15 ■ Automated rapid plasma regain (RPR) tests have been introduced in clinical laboratories,  
16  
17 so we compared the automated test to conventional RPR card tests.  
18  
19
- 20 ■ The automated RPR showed overall lower sensitivity compared to the conventional RPR  
21  
22 when comparing to treponemal test, TPPA.  
23  
24
- 25 ■ The automated RPR showed higher seroconversion after treatment than the conventional  
26  
27 manual RPR. So, the automated RPR test may be used to monitor treatment response,  
28  
29 especially in the reverse screening algorithm for syphilis testing.  
30  
31
- 32 ■ Limitations of this study could be considered, including small sample size and the patient  
33  
34 groups could not accurately categorized according to the stage because of low prevalence  
35  
36 of syphilis in Korea.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have decreased, and the prevalence rate is still very low.<sup>1</sup> Despite these low rates, syphilis is an important infection because it can cause serious health problems including neurosyphilis and congenital infection. So, appropriate screening, confirmation, and follow-up protocols are well established.<sup>2-4</sup> Serological analysis of non-treponemal reagent tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, fluorescent treponemal antibody absorption test (FTA-ABS) and Treponema-specific antibody test have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2,5,6</sup> A non-treponemal reagent test is still recommended by the CDC to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been widely used, the VDRL and RPR methods. RPR is the most common first-line non-treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have been introduced but variable results were reported when comparing the automated test to conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the conventional RPR card test such as greater capacity to deal with a large number of samples, minimal person-to-person variation, and simple automated procedures.

The aim of this study was to evaluate the possible benefits of an automated RPR test

1  
2  
3  
4 compared to a conventional RPR card test in clinical application.  
5  
6  
7

## 8 **METHODS**

### 9 **Subjects**

10  
11  
12  
13  
14  
15 A total of 112 serum samples from 59 syphilis patients ( $48\pm 21$  years-old, Male to Female =  
16  
17 25:34, ratio = 0.7) and 53 non-syphilitic controls ( $45\pm 17$  years-old, Male to Female = 27:26,  
18  
19 ratio = 1) after treponemal test were collected from November 2012 to April 2013 in a  
20  
21 university hospital in Korea. Remnant sera from requested treponemal test after confirmation  
22  
23 were included and preserved at  $-70^{\circ}\text{C}$  until analysis. Patients were not categorized according  
24  
25 to the syphilis stage due to the infrequency of syphilis infection. True syphilis patients were  
26  
27 very rare because of its low prevalence in this country. This study targeted to evaluate the  
28  
29 same RPR tests with ethically protected remnant specimens. This case was Institutional  
30  
31 Review Board (IRB) exempted in our institution.  
32  
33

34  
35 The automated RPR test was compared with manual card RPR Test (Becton Dickinson BD  
36  
37 Microbiology Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was  
38  
39 performed by a *Treponema pallidum* particle agglutination assay (TPPA) according to the  
40  
41 manufacturer's instructions. Seroconversion rates of each non-treponemal RPR tests were  
42  
43 evaluated with 23 syphilitic patients who had medical history of syphilis treatment.  
44  
45  
46  
47

### 48 **Serologic tests**

#### 49 **Conventional RPR card test**

50  
51  
52  
53 The Macro-Vue RPR Card test (Becton Dickinson BD Microbiology Systems, Sparks, MD,  
54  
55 USA) uses cardiolipin antigen with a carbon particle to detect reagin. Reagin binds to the test  
56  
57  
58  
59  
60

1  
2  
3  
4 antigen, which consists of cardiolipin-lecithin-cholesterol particles, causing macroscopic  
5  
6 flocculation. Controls were established in each testing to confirm optimal reactivity of the  
7  
8 antigen. The test procedure was followed according to the manufacturer's instructions.  
9

### 10 11 12 13 **Automated RPR**

14  
15 HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) is a latex turbidimetric  
16  
17 immunoassay using latex particles coated with lecithin and cardiolipin. The latex particle  
18  
19 reacts with the reagin in the serum of syphilis patients. The 15  $\mu\text{L}$  serum samples were  
20  
21 reacted with 120  $\mu\text{L}$  Hisens auto RPR LTIA R1 (buffer) and 60  $\mu\text{L}$  Hisens auto RPR LTIA R2  
22  
23 (latex reagent containing cardiolipin-lecithin-cholesterol 1.0 mg/mL) in CA-400 autoanalyzer  
24  
25 (Furuno Electric Co., Ltd. Nishinomiya, Japan). The CA-400 photometric analyzer was used  
26  
27 for the automated procedure and analysis. The absorbance at 600 nm was read after 5.3  
28  
29 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens auto RPR  
30  
31 equal to or greater than 1.0 RPR unit (R.U.) were considered as reactive RPR. The upper  
32  
33 detection limit was 20 R.U..  
34  
35  
36  
37  
38  
39

### 40 41 42 ***Treponema pallidum* particle agglutination (TPPA)**

43  
44 The Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) is based on the agglutination of  
45  
46 colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain)  
47  
48 antigen. For each specimen, a 100  $\mu\text{L}$  sample of diluent and 25  $\mu\text{L}$  of test specimen were  
49  
50 mixed first and 2-fold serial dilutions were made with 25  $\mu\text{L}$  of sample diluent. The sensitized  
51  
52 particles were serially mixed in the next wells with a plate mixer for 30 seconds. After 2  
53  
54 hours of incubation at room temperature, the result of the agglutination assay was read. The  
55  
56 Serodia TPPA assay results were interpreted by the agglutination patterns with positive and  
57  
58  
59  
60

1  
2  
3  
4 negative controls.  
5  
6  
7

### 8 **Statistical analyses**

9  
10 The percent agreement, kappa coefficient, of automated RPR test with manual RPR card test  
11 was calculated. The overall sensitivity and specificity of each test were calculated based on  
12 the data from TPPA results. Kappa values were used to categorize results as very good (0.81  
13 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or poor (0 to 0.2).<sup>9</sup> The  
14 McNemar test was used to compare the seroconversion rate between the automated RPR test  
15 and the conventional manual RPR card test and was performed by SPSS Statistics Version 20  
16 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was considered statistically  
17 significant.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **RESULTS**

31  
32 The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709,  
33 Table 1). The strength of agreement between the automated RPR test and manual RPR card  
34 test was considered to be “moderate” according to the kappa value scale. The specimens of  
35 both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR  
36 negative results (n=56) showed 85.7% (48/56) TPPA-negative results.  
37 There were 24 discrepant results (21.4%) between the two RPR tests, including 22 negative  
38 cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the BD  
39 Macro-Vue RPR card test. Of these 22 discrepant results, 20 cases were TPPA-positive and 2  
40 cases were TPPA-negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA  
41 test but negative in the BD Macro-Vue RPR card test. These 2 cases were negative in the  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 TPPA test. There were 4 results with discrepancies between both of the RPR tests and the  
5  
6 TPPA assay which were due to conditions other than syphilis infections (Table 2). The  
7  
8 strength of agreement between the automated RPR and manual RPR card tests was “fair”  
9  
10 (kappa value: 0.296, 59 TPPA positive results; 0.293, 53 TPPA negative results) according to  
11  
12 TPPA results (Table 3).

13  
14 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
15  
16 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95% CI: 84.3%-98.8%), respectively.  
17  
18 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
19  
20 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
21  
22 gave a higher seroconversion rate after syphilis treatment, with a value of 43.5% (10/23),  
23  
24 than that of the conventional RPR card test, which was 4.3% (1/23,  $p=0.004$ ) by McNemar  
25  
26 test. Detailed comparison results of treated syphilis cases are described in Table 5.  
27  
28  
29  
30  
31

## 32 DISCUSSION

33  
34 Manual RPR test has been used for decades, and recently the automated RPR test method  
35  
36 was launched and has been used because of its convenience in clinical settings. However,  
37  
38 there has been the need to thorough inspection and comparing results of this new automated  
39  
40 test to conventional manual RPR test in the diagnostic approaches. The treponemal test  
41  
42 results will not change even after treatment, and the patients live with positive results for the  
43  
44 remainder of their lives regardless of treatment or disease activity. Treponemal tests cannot  
45  
46 discriminate between past infections, active disease, treated patients, and non-treated  
47  
48 patients.<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have  
49  
50 been treated during the primary or secondary stage of the disease. When the primary or  
51  
52 secondary stage of a first *T. pallidum* infection is treated, nontreponemal test titer should  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 show a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> Therefore, non-  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

show a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> Therefore, non-treponemal test is important for managing syphilitic patients.

We compared an automated RPR test with a conventional RPR card test in the sera confirmed by TPPA. The TPPA test is also known to be less subjective than the FTA-ABS and easier to read than the microhemagglutination assay for antibodies to *Treponema pallidum* (MHA-TP).<sup>11</sup> TPPA has also been suggested to be applied to CSF samples to diagnose neurosyphilis.<sup>12</sup>

In our study, the conventional BD Macro-Vue RPR card test showed better sensitivity than did the HBI HiSens Auto RPR LTIA test in syphilis screening. Though, the automated RPR test does have some advantages in the clinical settings. For example, the automated RPR test reduced the workload and overall test turn-around time. It also can deal with greater test quantities in a given time than the manual RPR card test, and does not require test experts. Also, we noticed that the automated RPR test could be used as a monitoring marker of treatment response, especially if treponemal tests are used for first-line screening of syphilis as a reverse algorithm of syphilis testing. Recently, this reverse algorithm for syphilis testing has been suggested and has been adopted in many jurisdictions because this approach may be more sensitive and effective than the traditional algorithm<sup>3 4 6</sup> in a low prevalence area and could be automated. However, the Centers for Disease Control and Prevention (CDC) still recommend screening for syphilis with a non-treponemal test first, such as RPR.<sup>2</sup>

Our study presented that the automated RPR test showed earlier seroconversion than conventional card RPR test after syphilis treatment ( $p=0.004$ ). If we adopt the reverse algorithm, it could be used that the treponemal tests screen sensitively first and then the non-treponemal tests accurately show negative change in treated cases. In this situation we could use treponemal tests for first-line screening and non-treponemal tests for monitoring the

1  
2  
3  
4 patients to see seroconversion more effectively after treatment.<sup>2 13 14</sup> Unfortunately, our study  
5  
6 had a limited number of syphilitic patients due to low prevalence rate of syphilis in our  
7  
8 country and the number of samples was small and could not be classified according to  
9  
10 syphilis stage. In fact, some late or latent syphilis cases were hard to interpret the results of  
11  
12 non-treponemal test after initial treatment in our study (Case No. 8 or 9 in Table 5). So, further  
13  
14 well designed studies will be needed to clarify the serologic responses of automated RPR  
15  
16 tests after treatment and according to the stage of syphilis infection.  
17  
18

19  
20 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
21  
22 evaluations comparing conventional RPR tests and VDRL tests were reported.<sup>8 15</sup> However,  
23  
24 the results were variable. Tomohiko et al. also suggested that when the automated serological  
25  
26 testing method is used in clinical settings, the same reagent should be consistently selected to  
27  
28 evaluate the changes in antibody titers because the manual serological testing method for  
29  
30 syphilis showed somewhat different results from the automated serological testing methods.<sup>16</sup>  
31  
32 In this study, we noticed moderately consistent results between automated RPR and manual  
33  
34 RPR.  
35  
36

37  
38 We found that the automated RPR has a greater processing capability within a limited time  
39  
40 and is effectively applicable. Through the reverse syphilis screening algorithm, we can  
41  
42 increase the detection sensitivity of syphilis screening by treponemal test screening initially  
43  
44 and the automated RPR test may be used after treatment for its rapid seroconversion, though  
45  
46 the sensitivity of automated RPR is lower than manual RPR.  
47

48  
49 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
50  
51 specificity compared to the conventional manual RPR card test. Therefore, we thought that  
52  
53 automated RPR is not matched to use as initial screening of syphilis. However, the automated  
54  
55 RPR seems to be earlier seroconversion response in treated cases than those of conventional  
56  
57  
58  
59  
60

1  
2  
3  
4 RPR card test. If reverse algorithm is applied, sensitive treponemal tests were used in first  
5  
6 line, and then the automated RPR might be used as adjunct to detect earlier seroconversion in  
7  
8 treated patients.  
9

10  
11 Further large-scale studies including well-categorized patients by syphilis stage are  
12  
13 warranted to clarify the accurate diagnostic efficiency of the automated RPR test.  
14

### 15 16 17 **Author affiliations** 18

19  
20  
21 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea  
22

23 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea  
24

25 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
26  
27  
28

### 29 30 31 **Contributors** 32

33 Hyon-Suk Kim designed and participated in all the stages of this study. Jong-Han Lee  
34  
35 participated in the experiments and in statistical analyses and draft the manuscript. Chae  
36  
37 Seung Lim and Min-Geol Lee helped to consultations of this study. All authors read and  
38  
39 approved the final manuscript.  
40  
41  
42  
43  
44  
45

### 46 47 **Funding** 48

49 None  
50  
51

### 52 53 **Competing interests** 54

55 None.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 **Provenance and peer review**  
7

8 Not commissioned; externally peer reviewed.  
9  
10

11  
12 **Data sharing statement**  
13

14 No additional data are available.  
15

16  
17 No data sharing  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep* 2011;60:133-7.
- 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLS Syphilis Serology Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 4 French P, Gomberg M, Janier M, *et al.* IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin Infect Dis* 2012;25:79-85.
- 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 8 Kim YS, Lee J, Lee HK, *et al.* [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab Med* 2009;29:331-7.
- 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
- 11 Castro RR, Prieto ES, Santo I, *et al.* Evaluation of the passive particle agglutination

- 1  
2  
3  
4 test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.  
5  
6 12 Castro R, Prieto ES, Aguas MJ, *et al.* Evaluation of the *Treponema pallidum* particle  
7 agglutination technique (TPPA) in the diagnosis of neurosyphilis. *J Clin Lab Anal*  
8 2006;20:233-8.  
9  
10  
11  
12 13 Romanowski B, Sutherland R, Fick GH, *et al.* Serologic response to treatment of  
14 infectious syphilis. *Ann Intern Med* 1991;114:1005-9.  
15  
16  
17 14 Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a  
18 paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-  
19 8.  
20  
21  
22  
23  
24 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with  
25 conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.  
26  
27  
28 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the  
29 manual and automated serological testing methods for syphilis. *J Dermatol*  
30 2012;39:355-61.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Licence for Publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.



**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)

Kappa= 0.565

95% confidence interval: 0.422 to 0.709

<sup>1)</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were negative in TPPA test.

<sup>2)</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.

Abbreviations: RPR, rapid plasma reagin.

**Table 2** Discrepant RPR results to treponemal test for diagnosis of syphilis

Case No.	Age /Sex	RPR card test	Automated RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 3** Comparison of non-treponemal RPR tests according to *Treponema pallidum* particle agglutination (TPPA) test results

TPPA positive (n=59)				TPPA negative (n=53)			
		HBI HiSens Auto RPR				HBI HiSens Auto RPR	
		Positive	Negative			Positive	Negative
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48
Number of observed agreements: 39 (66.1% of the observations)				Number of observed agreements: 49 (92.5% of the observations)			
Kappa= 0.296				Kappa= 0.293			
95% confidence interval: 0.118 to 0.474				95% confidence interval: -0.212 to 0.798			
Abbreviations: RPR, rapid plasma regain; TPPA, <i>Treponema pallidum</i> particle agglutination.							

**Table 4** Performance characteristics of RPR tests for diagnosis syphilis

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive	31	3
	Negative	28	50
Sensitivity	52.5%	(95% CI: 39.1 % to 65.7 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	91.2%	(95% CI: 76.3 % to 98 %)	
Negative predictive value	64.1%	(95% CI: 52.4 % to 74.7 %)	
	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive	51	3
	Negative	8	50
Sensitivity	86.4%	(95% CI: 75 % to 93.9 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	94.4 %	(95% CI: 84.6 % to 98.8 %)	
Negative predictive value	86.2 %	(95% CI: 74.6 % to 93.8 %)	

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Pretreatment VDRL test value	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	1:8 reactive	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	1:1 weakly reactive	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	1:4 reactive	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	1:1 reactive	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	1:1 weakly reactive	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	1:1 weakly reactive	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	N/A	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	1:1 weakly reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	1:1 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1+	0	1:5120	1:8 reactive	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1:1 reactive	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	1:32 reactive	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	1:1 reactive	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	1:1 reactive	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	1:1 weakly reactive	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	1:2 reactive	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	1:4 reactive	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	1:8 reactive	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	1:8 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	1:16 reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	1:16 reactive	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	1:8 reactive	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	1:16 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination; N/A, not applicable.

1  
2  
3  
4  
5  
6  
7  
8 **Original article**

9  
10  
11 **Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR**  
12 **card test in syphilis testing**  
13  
14

15  
16  
17 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>

18  
19  
20  
21 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

22  
23 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

24  
25 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
26  
27  
28  
29  
30  
31

32 Correspondence: Hyon-Suk Kim

33 E-mail: kimhs54@yuhs.ac

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tel: (+82) 2-2228-2443

Fax: (+82) 2-364-1583

Department of Laboratory Medicine, Yonsei University College of Medicine

50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea

Running title: Automated RPR test for syphilis testing

Number of words: ~~2,117;2,140~~; Number of abstract: ~~270~~274

0 Figures, 5 Tables, and 16 References

Style Definition: Header

Style Definition: Footer

Style Definition: Balloon Text

Style Definition: Comment Text

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** ~~A Method~~ comparative study of lab methods using clinical specimens in a single institute.

**Participants:** A total of 112 serum samples including 59 TPPA- (*Treponema pallidum* particle agglutination) positive and 53 TPPA-negative specimens were included for this evaluation.

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the automated RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed more seroconversion~~higher seronegative~~ changes (43.5%, 10/23) than the manual RPR card test (4.3%, 1/23) in treated patients.

1  
2  
3  
4  
5  
6  
7  
8 **Conclusions:** The automated RPR test showed overall lower sensitivity compared to  
9 ~~conventional manual~~ RPR test based on treponemal test. But, the automated RPR test showed  
10 more seroconversion, TPPA, probably due to higher seronegative conversion after treatment than the  
11 conventional RPR card test. ~~The~~ So, the automated RPR test might be used more useful to  
12 monitor treatment response, ~~than the conventional RPR card test~~, especially in the reverse  
13 screening algorithm in syphilis testing. ~~..~~

14  
15  
16  
17  
18  
19  
20 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement

#### 21 22 23 24 25 **Strengths and limitations of this study**


- 26  
27  
28 ■ Automated rapid plasma regain (RPR) tests have been introduced in clinical laboratories,  
29 so we compared the automated test to conventional RPR card tests.
- 30  
31  
32 ■ The automated RPR showed overall lower sensitivity compared to the  
33 ~~conventional manual~~ RPR when comparing to treponemal test, TPPA.
- 34  
35  
36  
37 ■ The automated RPR showed higher seroconversion conversion after treatment than the  
38 conventional manual RPR. So, the automated RPR test may be used more useful to  
39 monitor treatment response, ~~than the conventional manual RPR~~, especially in the reverse  
40 screening algorithm for syphilis testing.
- 41  
42  
43  
44  
45  
46  
47  
48  
49 ■ Limitations of this study could be considered, including small sample size and the patient  
50 groups could not accurately categorized according to the stage because of low prevalence  
51 of syphilis ~~infection in~~ Korea.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

| \_\_\_\_\_

For peer review only



## INTRODUCTION

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have decreased, and the prevalence rate is still very low.<sup>1</sup> ~~Despite these low rates, Even though,~~ syphilis is an important infection because it can cause serious health problems including neurosyphilis and congenital infection. So, appropriate screening, confirmation, and follow-up protocols are well established.<sup>2-4</sup> Serological analysis of non-treponemal reagin tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, fluorescent treponemal antibody absorption test (FTA-ABS) and Treponema-specific antibody test have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2,5,6</sup> A non-treponemal reagin test is still recommended by the CDC to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been widely used, the VDRL and RPR methods. RPR is the most common first-line non-treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have been introduced but variable results were reported when comparing the automated test to conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the conventional RPR card test such as greater capacity to deal with a large ~~number of~~ ~~seale~~ samples, minimal person-to-person variation, ~~and~~ simple automated ~~procedures, procedures, and rapid reports with good analytical performances.~~

The aim of this study was to evaluate the possible benefits of an automated RPR test

Formatted: Justified, Space After: 10 pt, Widow/Orphan control, Adjust space between Latin and Asian text, Adjust space between Asian text and numbers

1  
2  
3  
4  
5  
6  
7  
8 compared to a conventional RPR card test in clinical application.  
9

## 10 11 **METHODS**

### 12 13 14 15 **Subjects**

16  
17 A total of 112 serum samples from 59 syphilis patients (48±21 years-old, Male to Female =  
18 25:34, ratio = 0.7) and 53 non-syphilic controls (45±17 years-old, Male to Female =  
19 25:34) and 53 non-syphilic controls (45±17 years-old, Male to Female =  
20 27:26, ratio = 1) were collected after treponemal test ~~were collected~~ completed from  
21 November 2012 to April 2013 in a university hospital in Korea. Remnant sera from requested  
22 treponemal test after confirmation were included and preserved at -70 °C until analysis.  
23  
24

25  
26 Patients were not categorized according to the syphilis stage due to the infrequency of  
27 syphilis infection. True syphilis patients were very rare because of its low prevalence in this  
28 country. This study targeted to evaluate the same RPR tests with ethically protected remnant  
29 specimens. This case was Institutional Review Board (IRB) exempted in our institution. There  
30 was a report that only 1,424 cases are registered in Korean Centers for Control and  
31 Prevention (KCDC) in 2007.  
32  
33  
34  
35  
36  
37  
38

39 The automated RPR test was compared with manual card RPR Test (Becton Dickinson BD  
40 Microbiology Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was  
41 performed by a *Treponema pallidum* particle agglutination assay (TPPA) according to the  
42 manufacturer's instructions. Seroconversion rates of each non-treponemal RPR tests were  
43 evaluated with 23 syphilic patients who had medical history of syphilis treatment.  
44  
45  
46  
47  
48

### 49 50 **Serologic tests**

#### 51 52 **Conventional RPR card test**

1  
2  
3  
4  
5  
6  
7  
8 The Macro-Vue RPR Card test (Becton Dickinson BD Microbiology Systems, Sparks, MD,  
9 USA) uses cardiolipin antigen with a carbon particle to detect reagin. Reagin binds to the test  
10 antigen, which consists of cardiolipin-lecithin-cholesterol particles, causing macroscopic  
11 flocculation. Controls were established in each testing to confirm optimal reactivity of the  
12 antigen. The test procedure was followed according to the manufacturer's instructions.  
13  
14  
15  
16

### 17 18 19 **Automated RPR**

20  
21 HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) is a latex turbidimetric  
22 immunoassay using latex particles coated with lecithin and cardiolipin. The latex particle  
23 reacts with the reagin in the serum of syphilis patients. The 15  $\mu\text{L}$  serum samples were  
24 reacted with 120  $\mu\text{L}$  Hisens auto RPR LTIA R1 (buffer) and 60  $\mu\text{L}$  Hisens auto RPR LTIA R2  
25 (latex reagent containing cardiolipin-lecithin-cholesterol 1.0 mg/mL) in CA-400 autoanalyzer  
26 (Furuno Electric Co., Ltd. Nishinomiya, Japan). The CA-400 photometric analyzer was used  
27 for the automated procedure and analysis. The absorbance at 600 nm was read after 5.3  
28 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens auto RPR  
29 equal to or greater than 1.0 RPR unit (R.U.) were considered as reactive RPR. The upper  
30 detection limit was 20 R.U..  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 ***Treponema pallidum* particle agglutination (TPPA)**

43  
44 The Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) is based on the agglutination of  
45 colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain)  
46 antigen. For each specimen, a 100  $\mu\text{L}$  sample of diluent and 25  $\mu\text{L}$  of test specimen were  
47 mixed first and 2-fold serial dilutions were made with 25  $\mu\text{L}$  of sample diluent. The sensitized  
48 particles were serially mixed in the next wells with a plate mixer for 30 seconds. After 2  
49  
50  
51  
52  
53  
54

1  
2  
3  
4  
5  
6  
7  
8 hours of incubation at room temperature, the result of the agglutination assay was read. The  
9 Serodia TPPA assay results were interpreted by the agglutination patterns with positive and  
10 negative controls.  
11  
12

### 13 14 15 **Statistical analyses**

16  
17 The percent agreement, kappa coefficient, of automated RPR test with manual RPR card test  
18 was calculated. The overall sensitivity and specificity of each test were calculated based on  
19 the data from TPPA results. Kappa values were used to categorize results as very good (0.81  
20 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or poor (0 to 0.2).<sup>9</sup> The  
21 McNemar test was used to compare the seroconversion rate between the automated RPR test  
22 and the conventional manual RPR card test and was performed by SPSS Statistics Version 20  
23 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was considered statistically  
24 significant.  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **RESULTS**

35  
36  
37  
38 The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709,  
39 Table 1). The strength of agreement between the automated RPR test and manual RPR card  
40 test was considered to be “moderate” according to the kappa value scale. The specimens of  
41 both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR  
42 negative results (n=56) showed 85.7% (48/56) TPPA-negative results.  
43  
44  
45  
46  
47

48 There were 24 discrepant results (21.4%) between the two RPR tests, including 22 negative  
49 cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the BD  
50 Macro-Vue RPR card test. ~~And there were two false positive cases in HiSens Auto RPR LTIA~~  
51  
52  
53  
54

1  
2  
3  
4  
5  
6  
7  
8 ~~test~~. Of these 22 discrepant results, 20 cases were TPPA-positive and 2 cases were TPPA-  
9 negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA test but negative in  
10 the BD Macro-Vue RPR card test. These 2 cases were negative in the TPPA test. There were  
11 4 results with discrepancies between both of the RPR tests and the TPPA assay which were  
12 due to conditions other than syphilis infections (Table 2). The strength of agreement between  
13 the automated RPR and manual RPR card tests was “fair” (kappa value: 0.296, 59 TPPA  
14 positive results; 0.293, 53 TPPA negative results) according to TPPA results (Table 3).  
15  
16 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
17 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively.  
18  
19 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
20 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
21 gave a higher ~~seronegative~~ conversion rate after syphilis treatment, with a value of 43.5%  
22 (10/23), than that of the conventional RPR card test, which was 4.3% (1/23, p=0.004) by  
23 McNemar test. Detailed comparison results of treated syphilis cases are described in Table 5.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 DISCUSSION

37  
38 Manual RPR test has been used for decades, and recently the automated RPR test method  
39 was launched and has been used because of its convenience in clinical settings. However,  
40 there has been the need to thorough inspection and comparing results of this new automated  
41 test to conventional manual RPR test in the diagnostic approaches. The treponemal test  
42 results will not change even after treatment, and the patients live with positive results for the  
43 remainder of their lives regardless of treatment or disease activity. Treponemal tests cannot  
44 discriminate between ~~the~~ past infections, active disease, treated patients, and non-treated  
45 patients.<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

been treated during the primary or secondary stage of the disease. When the primary or secondary stage of a first *T. pallidum* infection is treated, nontreponemal test titer should show a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> Therefore, nontreponemal test is important for managing ~~the~~ syphilitic patients.

We compared an automated RPR test with a conventional RPR card test in the sera confirmed ~~by patients' sera with~~ TPPA. ~~The TPPA test was reported to be as sensitive as the FTA-ABS test in all the stages of syphilis and as useful as the RPR test for monitoring therapy.~~ The TPPA test is also known to be less subjective than the FTA-ABS and easier to read than the microhemagglutination assay for antibodies to *Treponema pallidum* (MHA-TP).<sup>11</sup> TPPA has also been suggested to be applied to CSF samples to diagnose neurosyphilis.<sup>12</sup>

In our study, the conventional BD Macro-Vue RPR card test showed better sensitivity than did the HBI HiSens Auto RPR LTIA test in syphilis screening. ~~Though~~ ~~But~~, the automated RPR test does have some advantages in the clinical settings. For example, the automated RPR test reduced the workload and overall test turn-around time. It also can deal with greater test quantities in a given time than the manual RPR card test, and does not require test experts.

Also, we noticed that the automated RPR test could be used as a ~~useful~~ monitoring marker of treatment response, especially if treponemal-~~specific~~ tests are used for first-line screening of syphilis as a reverse algorithm of syphilis testing. Recently, this reverse algorithm for syphilis testing has been suggested and has been adopted in many jurisdictions ~~began to adopt~~ because this approach may be more sensitive and effective than the traditional algorithm<sup>3 4 6</sup> in a low prevalence area and could be automated. However, the Centers for Disease Control and Prevention (CDC) still recommend screening for syphilis with a non-treponemal test first, such as RPR.<sup>2</sup>

~~The automated non-treponemal test has an additional important advantage over the~~

1  
2  
3  
4  
5  
6  
7  
8 ~~conventional manual non-treponemal test in addition to those previously described.~~ Our study  
9 presented that the automated RPR test showed earlier ~~seronegative~~ conversion than  
10 conventional card RPR test after syphilis treatment ( $p=0.004$ ). If we adopt the reverse  
11 algorithm, it could be ~~used ideal in~~ that the treponemal tests screen sensitively first and then  
12 the non-treponemal tests accurately show negative ~~change~~ in treated cases. In this situation  
13 we could use treponemal tests for first-line screening and non-treponemal tests for monitoring  
14 the patients to see ~~seronegative~~ conversion more effectively after treatment.<sup>2 13 14</sup>

15  
16  
17  
18  
19  
20  
21 Unfortunately, our study had a limited number of syphilitic patients due to low prevalence  
22 rate of syphilis in our country and the number of samples was small and could not been  
23 classified according to syphilis stage. In fact, some late or latent syphilis cases were hard to  
24 interpret the results of non-treponemal test after initial treatment in our study (Case No. 8 or 9  
25 in Table 5). So, further well designed studies will be needed to clarify the serologic responses  
26 of automated RPR tests after treatment and according to the stage of syphilis infection.

27  
28  
29  
30  
31  
32 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
33 evaluations comparing conventional RPR tests and VDRL tests were reported.<sup>8 15</sup> However,  
34 the results were variable. Tomohiko et al. also suggested that when the automated serological  
35 testing method is used in clinical settings, the same reagent should be consistently selected to  
36 evaluate the changes in antibody titers because the manual serological testing method for  
37 syphilis showed somewhat different results from the automated serological testing methods.<sup>16</sup>

38  
39  
40  
41  
42  
43  
44 In this study, we noticed moderately consistent results between ~~automated~~ RPR and manual  
45 RPR.

46  
47  
48 We found that the automated RPR has a greater processing capability within a limited time  
49 and is ~~more~~ effectively applicable ~~in a reverse syphilis screening algorithm~~. Through the  
50 reverse syphilis screening algorithm, we ~~cannot~~ increase the detection sensitivity of  
51  
52  
53



1  
2  
3  
4  
5  
6  
7 syphilis screening ~~by treponemal test screening initially~~, and the automated RPR test may be  
8 ~~used useful~~ after treatment for its rapid ~~seroconversion, seronegative conversion~~. The  
9 ~~automated RPR could be more useful in the treated cases~~ though ~~the it's~~ sensitivity of  
10 ~~automated RPR~~ is lower ~~than manual RPR after treatment~~.

Formatted: Font: Not Bold

11  
12  
13  
14  
15 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
16  
17 specificity compared to the conventional manual RPR card test. ~~Therefore, we thought that~~  
18 ~~automated RPR is not matched to use as initial screening of syphilis~~. However, the automated  
19  
20 RPR ~~seems to test may~~ be ~~earlier more helpful to monitor the~~ seroconversion responses in  
21  
22 treated ~~cases than those of conventional RPR card test~~. ~~If syphilis patients, especially in the~~  
23  
24 reverse ~~syphilis screening~~ algorithm ~~is applied, sensitive treponemal tests were used in first~~  
25  
26 ~~line, and then the automated RPR might be used as adjunct to detect earlier seroconversion in~~  
27  
28 ~~treated patients~~.

29  
30  
31 -Further large-scale studies including well-categorized patients by syphilis stage are  
32  
33 warranted to clarify the accurate diagnostic efficiency of the automated RPR test.

#### 34 35 36 **Author affiliations**

37  
38  
39  
40 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

41  
42 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

43  
44 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea

#### 45 46 47 **Contributors**

48  
49 Hyon-Suk Kim designed and participated in all the stages of this study. Jong-Han Lee  
50  
51 participated in the experiments and in statistical analyses and draft the manuscript. Chae  
52  
53

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Seung Lim and Min-Geol Lee helped to consultations of this study. All authors read and approved the final manuscript.

**Funding**

None

**Competing interests**

None.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

No additional data are available.


[No data sharing](#)

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## REFERENCES

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly*

15

Formatted: Left, Line spacing: single, Widow/Orphan control, Adjust space between Latin and Asian text, Adjust space between Asian text and numbers

- 1  
2  
3  
4  
5  
6  
7  
8 *Rep* 2011;60:133-7.
- 9  
10 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLS Syphilis Serology  
11 Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 12  
13 4 French P, Gomberg M, Janier M, *et al*. IUSTI: 2008 European Guidelines on the  
14 Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 15  
16  
17 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin*  
18 *Infect Dis* 2012;25:79-85.
- 19  
20  
21 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening  
22 tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 23  
24  
25 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory  
26 immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 27  
28  
29 8 Kim YS, Lee J, Lee HK, *et al*. [Comparison of quantitative results among two  
30 automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab*  
31 *Med* 2009;29:331-7.
- 32  
33  
34 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data.  
35 *Biometrics* 1977;33:159-74.
- 36  
37  
38 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted  
39 diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
- 40  
41  
42 11 Castro RR, Prieto ES, Santo I, *et al*. Evaluation of the passive particle agglutination  
43 test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.
- 44  
45  
46 12 Castro R, Prieto ES, Aguas MJ, *et al*. Evaluation of the *Treponema pallidum* particle  
47 agglutination technique (TP.PA) in the diagnosis of neurosyphilis. *J Clin Lab Anal*  
48 2006;20:233-8.
- 49  
50  
51  
52 13 Romanowski B, Sutherland R, Fick GH, *et al*. Serologic response to treatment of  
53  
54

- 1  
2  
3  
4  
5  
6  
7  
8 infectious syphilis. *Ann Intern Med* 1991;114:1005-9.
- 9  
10 14 Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a  
11 paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-  
12 8.
- 13  
14  
15 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with  
16 conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.
- 17  
18  
19 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the  
20 manual and automated serological testing methods for syphilis. *J Dermatol*  
21 2012;39:355-61.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### Licence for Publication statement

48 The Corresponding Author has the right to grant on behalf of all authors and does grant on  
49 behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a  
50 worldwide basis to the BMJ Group and co-owners or contracting owning societies (where  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Left, Line spacing: single, Widow/Orphan control, Adjust space between Latin and Asian text, Adjust space between Asian text and numbers

published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.

**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)  
 Kappa= 0.565  
 95% confidence interval: 0.422 to 0.709

1  
2  
3  
4  
5  
6  
7  
8 1)<sup>1</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were  
9 negative in TPPA test.

10 2)<sup>2</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.

11 Abbreviations: RPR, rapid plasma ~~reagin~~, ~~regain~~.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44 **Table 2** Discrepant RPR results to treponemal test for diagnosis of syphilis


Case No.	Age /Sex	RPR card test	Automated RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

51  
52 Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Table 3** Comparison of non-treponemal RPR tests according to *Treponema pallidum* particle agglutination (TPPA) test results

TPPA positive (n=59)	HBI HiSens Auto RPR		TPPA negative (n=53)	HBI HiSens Auto RPR			
	Positive	Negative		Positive	Negative		
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48

Number of observed agreements: 39 (66.1% of the observations)      Number of observed agreements: 49 (92.5% of the observations)  
 Kappa= 0.296      Kappa= 0.293  
 95% confidence interval: 0.118 to 0.474      95% confidence interval: -0.212 to 0.798

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.



**Table 4** Performance characteristics of RPR tests for diagnosis syphilis

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive	31	3
	Negative	28	50
Sensitivity	52.5%	(95% CI: 39.1 % to 65.7 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	91.2%	(95% CI: 76.3 % to 98 %)	
Negative predictive value	64.1%	(95% CI: 52.4 % to 74.7 %)	
BD Macro-Vue RPR card	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive	51	3
	Negative	8	50
Sensitivity	86.4%	(95% CI: 75 % to 93.9 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	94.4 %	(95% CI: 84.6 % to 98.8 %)	
Negative predictive value	86.2 %	(95% CI: 74.6 % to 93.8 %)	

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Pretreatment VDRL test value	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	1:8 reactive	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	1:1 weakly reactive	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	1:4 reactive	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	1:1 reactive	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	1:1 weakly reactive	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	1:1 weakly reactive	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	N/A	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	1:1 weakly reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	1:1 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1+	0	1:5120	1:8 reactive	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1:1 reactive	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	1:32 reactive	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	1:1 reactive	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	1:1 reactive	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	1:1 weakly reactive	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	1:2 reactive	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	1:4 reactive	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	1:8 reactive	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	1:8 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	1:16 reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	1:16 reactive	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	1:8 reactive	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	1:16 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination; N/A, not applicable.

Formatted: Korean

23

**STARD checklist for reporting of studies of diagnostic accuracy**  
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	4
<b>METHODS</b>			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	5
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	5
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	5
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	5
<i>Test methods</i>	7	The reference standard and its rationale.	6
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	5-6
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	5-6
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	N/A
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	5-6
	13	Methods for calculating test reproducibility, if done.	N/A
<b>RESULTS</b>			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	5
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	5
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	N/A
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	N/A
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	7
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	7
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	8-10

# BMJ Open

## Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR card test in syphilis testing

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005664.R4
Article Type:	Research
Date Submitted by the Author:	21-Nov-2014
Complete List of Authors:	Lee, Jong-Han; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lim, Chae Seung; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea, Lee, Min-Geol; Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea, Kim, Hyon-Suk; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Infectious diseases, Diagnostics
Keywords:	Public health < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES, IMMUNOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Original article**  
5

6  
7  
8 **Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR**  
9 **card test in syphilis testing**  
10  
11

12  
13  
14  
15 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>  
16

17  
18  
19 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea  
20

21 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea  
22

23 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Correspondence: Hyon-Suk Kim  
34

35 E-mail: kimhs54@yuhs.ac  
36

37 Tel: (+82) 2-2228-2443  
38

39 Fax: (+82) 2-364-1583  
40

41 Department of Laboratory Medicine, Yonsei University College of Medicine  
42

43 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea  
44  
45  
46  
47

48 Running title: Automated RPR test for syphilis testing  
49

50 Number of words: 2,164; Number of abstract: 270  
51

52 0 Figures, 5 Tables, and 16 References  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** A comparative study of lab methods using clinical specimens in a single institute.

**Participants:** A total of 112 serum samples including 59 TPPA- (*Treponema pallidum* particle agglutination) positive and 53 TPPA-negative specimens were included for this evaluation.

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the automated RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed more seroconversion changes (43.5%, 10/23) than the conventional RPR card test (4.3%, 1/23) in treated patients.

**Conclusions:** The automated RPR test showed overall lower sensitivity compared to conventional RPR test based on treponemal test. But, the automated RPR test showed more seroconversion after treatment than the conventional RPR card test. The automated RPR test



1  
2  
3  
4 might be used to monitor treatment response, especially in the reverse screening algorithm in  
5  
6 syphilis testing.  
7  
8

9 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement  
10  
11

### 12 **Strengths and limitations of this study**

13  
14

- 15 ■ Automated rapid plasma regain (RPR) tests have been introduced in clinical laboratories,  
16  
17 so we compared the automated test to conventional RPR card tests.  
18  
19
- 20 ■ The automated RPR showed overall lower positivity compared to the conventional RPR  
21  
22 when comparing to treponemal test, TPPA.  
23  
24
- 25 ■ The automated RPR showed higher seroconversion after treatment than the conventional  
26  
27 manual RPR. So, the automated RPR test may be used to monitor treatment response,  
28  
29 especially in the reverse screening algorithm for syphilis testing.  
30  
31
- 32 ■ Limitations of this study could be considered, including small sample size and the patient  
33  
34 groups could not accurately categorized according to the stage because of low prevalence  
35  
36 of syphilis in Korea.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have decreased, and the prevalence rate is still very low.<sup>1</sup> Despite these low rates, syphilis is an important infection because it can cause serious health problems including neurosyphilis and congenital infection. Appropriate screening, confirmation, and follow-up protocols are required.<sup>2-4</sup> Serological analysis of non-treponemal reagin tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, fluorescent treponemal antibody absorption test (FTA-ABS) and Treponema-specific antibody test have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2,5,6</sup> A non-treponemal reagin test is still recommended by the CDC to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been widely used, the VDRL and RPR methods. RPR is the most common first-line non-treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have been introduced but variable results were reported when comparing the automated test to conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the conventional RPR card test such as greater capacity to deal with a large number of samples, minimal person-to-person variation, and simple automated procedures.

The aim of this study was to evaluate the possible benefits of an automated RPR test

1  
2  
3  
4 compared to a conventional RPR card test in clinical application.  
5  
6  
7

## 8 **METHODS**

### 9 **Subjects**

10  
11  
12 All positive sera for syphilis by one or more tests from November 2012 to April 2013 from a  
13 university hospital were included along with matched controls. Remnant sera from requested  
14 treponemal test after confirmation were included and preserved at -70 °C until analysis.  
15  
16  
17  
18  
19  
20  
21

22 Patients were not categorized according to the syphilis stage due to the infrequency of  
23 syphilis infection. True syphilis patients were very rare because of its low prevalence in this  
24 country. This study targeted to evaluate the same RPR tests with ethically protected remnant  
25 specimens. This case was Institutional Review Board (IRB) exempted in our institution. All  
26 the study processes were followed by the World Medical Association Declaration of Helsinki.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The automated RPR test was compared with manual card RPR Test (Becton Dickinson BD  
Microbiology Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was  
performed by a *Treponema pallidum* particle agglutination assay (TPPA) according to the  
manufacturer's instructions. Seroconversion rates of each non-treponemal RPR tests were  
evaluated with 23 syphilitic patients who had medical history of syphilis treatment.

### 56 **Serologic tests**

#### 57 **Conventional RPR card test**

58  
59  
60  
The Macro-Vue RPR Card test (Becton Dickinson BD Microbiology Systems, Sparks, MD,  
USA) uses cardiolipin antigen with a carbon particle to detect reagin. Reagin binds to the test  
antigen, which consists of cardiolipin-lecithin-cholesterol particles, causing macroscopic

1  
2  
3  
4 flocculation. Controls were established in each testing to confirm optimal reactivity of the  
5 antigen. The test procedure was followed according to the manufacturer's instructions.  
6  
7  
8  
9

### 10 11 **Automated RPR**

12  
13 HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) is a latex turbidimetric  
14 immunoassay using latex particles coated with lecithin and cardiolipin. The latex particle  
15 reacts with the reagin in the serum of syphilis patients. The 15 µL serum samples were  
16 reacted with 120 µL Hisens auto RPR LTIA R1 (buffer) and 60 µL Hisens auto RPR LTIA R2  
17 (latex reagent containing cardiolipin-lecithin-cholesterol 1.0 mg/mL) in CA-400 autoanalyzer  
18 (Furuno Electric Co., Ltd. Nishinomiya, Japan). The CA-400 photometric analyzer was used  
19 for the automated procedure and analysis. The absorbance at 600 nm was read after 5.3  
20 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens auto RPR  
21 equal to or greater than 1.0 RPR unit (R.U.) were considered as reactive RPR. The upper  
22 detection limit was 20 R.U..  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 ***Treponema pallidum* particle agglutination (TPPA)**

38  
39 The Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) is based on the agglutination of  
40 colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain)  
41 antigen. For each specimen, a 100 µL sample of diluent and 25 µL of test specimen were  
42 mixed first and 2-fold serial dilutions were made with 25 µL of sample diluent. The sensitized  
43 particles were serially mixed in the next wells with a plate mixer for 30 seconds. After 2  
44 hours of incubation at room temperature, the result of the agglutination assay was read. The  
45 Serodia TPPA assay results were interpreted by the agglutination patterns with positive and  
46 negative controls.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Statistical analyses

The percent agreement, kappa coefficient, of automated RPR test with manual RPR card test was calculated. The overall sensitivity and specificity of each test were calculated based on the data from TPPA results. Kappa values were used to categorize results as very good (0.81 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or poor (0 to 0.2).<sup>9</sup> The McNemar test was used to compare the seroconversion rate between the automated RPR test and the conventional manual RPR card test and was performed by SPSS Statistics Version 20 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was considered statistically significant.

### RESULTS

A total of 112 serum samples from 59 syphilis patients (48±21 years-old, Male to Female = 25:34, ratio = 0.7) and 53 non-syphilitic controls (45±17 years-old, Male to Female = 27:26, ratio = 1) after treponemal test were collected from November 2012 to April 2013 in a university hospital in Korea.

The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709, Table 1). The strength of agreement between the automated RPR test and manual RPR card test was considered to be “moderate” according to the kappa value scale. The specimens of both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR negative results (n=56) showed 85.7% (48/56) TPPA-negative results.

There were 24 discrepant results (21.4%) between the two RPR tests, including 22 negative cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the BD Macro-Vue RPR card test. Of these 22 discrepant results, 20 cases were TPPA-positive and 2

1  
2  
3  
4 cases were TPPA-negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA  
5  
6 test but negative in the BD Macro-Vue RPR card test. These 2 cases were negative in the  
7  
8 TPPA test. There were 4 results with discrepancies between both of the RPR tests and the  
9  
10 TPPA assay which were due to conditions other than syphilis infections (Table 2). The  
11  
12 strength of agreement between the automated RPR and manual RPR card tests was “fair”  
13  
14 (kappa value: 0.296, 59 TPPA positive results; 0.293, 53 TPPA negative results) according to  
15  
16 TPPA results (Table 3).

17  
18  
19 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
20  
21 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively.  
22  
23 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
24  
25 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
26  
27 gave a higher seroconversion rate after syphilis treatment, with a value of 43.5% (10/23),  
28  
29 than that of the conventional RPR card test, which was 4.3% (1/23,  $p=0.004$ ) by McNemar  
30  
31 test. Detailed comparison results of treated syphilis cases are described in Table 5.  
32  
33  
34  
35  
36

## 37 **DISCUSSION**

38  
39 Manual RPR test has been used for decades, and recently the automated RPR test method  
40  
41 was launched and has been used because of its convenience in clinical settings. However,  
42  
43 there has been the need to thorough inspection and comparing results of this new automated  
44  
45 test to conventional manual RPR test in the diagnostic approaches. The treponemal test  
46  
47 results will not change even after treatment, and the patients live with positive results for the  
48  
49 remainder of their lives regardless of treatment or disease activity. Treponemal tests cannot  
50  
51 discriminate between past infections, active disease, treated patients, and non-treated  
52  
53 patients.<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 been treated during the primary or secondary stage of the disease. When the primary or  
5  
6 secondary stage of a first *T. pallidum* infection is treated, nontreponemal test titer should  
7  
8 show a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> Therefore, non-  
9  
10 treponemal test is important for managing syphilitic patients.

11  
12 We compared an automated RPR test with a conventional RPR card test in the sera confirmed  
13  
14 by TPPA. The TPPA test is also known to be less subjective than the FTA-ABS and easier to  
15  
16 read than the microhemagglutination assay for antibodies to *Treponema pallidum* (MHA-  
17  
18 TP).<sup>11</sup> TPPA has also been suggested to be applied to CSF samples to diagnose  
19  
20 neurosyphilis.<sup>12</sup>

21  
22 In our study, the conventional BD Macro-Vue RPR card test showed better sensitivity than  
23  
24 did the HBI HiSens Auto RPR LTIA test in syphilis screening. Though, the automated RPR  
25  
26 test does have some advantages in the clinical settings. For example, the automated RPR  
27  
28 test reduced the workload and overall test turn-around time. It also can deal with greater test  
29  
30 quantities in a given time than the manual RPR card test, and does not require test experts.  
31  
32 Also, we noticed that the automated RPR test could be used as a monitoring marker of  
33  
34 treatment response, especially if treponemal tests are used for first-line screening of syphilis  
35  
36 as a reverse algorithm of syphilis testing. Recently, this reverse algorithm for syphilis testing  
37  
38 has been suggested and has been adopted in many jurisdictions because this approach may be  
39  
40 more sensitive and effective than the traditional algorithm<sup>3 4 6</sup> in a low prevalence area and  
41  
42 could be automated. However, the Centers for Disease Control and Prevention (CDC) still  
43  
44 recommend screening for syphilis with a non-treponemal test first, such as RPR.<sup>2</sup>

45  
46 Our study presented that the automated RPR test showed earlier seroconversion than  
47  
48 conventional card RPR test after syphilis treatment (p=0.004). If we adopt the reverse  
49  
50 algorithm, it could be used that the treponemal tests screen sensitively first and then the non-  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 treponemal tests accurately show negative change in treated cases. In this situation we could  
5  
6 use treponemal tests for first-line screening and non-treponemal tests for monitoring the  
7  
8 patients to see seroconversion more effectively after treatment.<sup>2 13 14</sup> Unfortunately, our study  
9  
10 had a limited number of syphilitic patients due to low prevalence rate of syphilis in our  
11  
12 country and the number of samples was small and could not be classified according to  
13  
14 syphilis stage. In fact, some late or latent syphilis cases were hard to interpret the results of  
15  
16 non-treponemal test after initial treatment in our study (Case No. 8 or 9 in Table 5). So,  
17  
18 further well designed studies will be needed to clarify the serologic responses of automated  
19  
20 RPR tests after treatment and according to the stage of syphilis infection.  
21  
22

23  
24 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
25  
26 evaluations comparing conventional RPR tests and VDRL tests were reported.<sup>8 15</sup> However,  
27  
28 the results were variable. Tomohiko et al. also suggested that when the automated serological  
29  
30 testing method is used in clinical settings, the same reagent should be consistently selected to  
31  
32 evaluate the changes in antibody titers because the manual serological testing method for  
33  
34 syphilis showed somewhat different results from the automated serological testing methods.<sup>16</sup>  
35  
36 In this study, we noticed moderately consistent results between automated RPR and manual  
37  
38 RPR.  
39  
40

41  
42 We found that the automated RPR has a greater processing capability within a limited time  
43  
44 and is effectively applicable. Through the reverse syphilis screening algorithm, we can  
45  
46 increase the detection sensitivity of syphilis screening by treponemal test screening initially  
47  
48 and the automated RPR test may be used after treatment for its rapid seroconversion, though  
49  
50 the sensitivity of automated RPR is lower than manual RPR.  
51

52  
53 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
54  
55 specificity compared to the conventional manual RPR card test. Therefore, we thought that  
56  
57



1  
2  
3  
4 automated RPR is not matched to use as initial screening of syphilis. However, the automated  
5  
6 RPR seems to be earlier seroconversion response in treated cases than those of conventional  
7  
8 RPR card test. If reverse algorithm is applied, sensitive treponemal tests are used as a first  
9  
10 line screening test, and then the automated RPR might be used as an adjunct to detect earlier  
11  
12 seroconversion in treated patients.

13  
14  
15 Further large-scale studies including well-categorized patients by syphilis stage are  
16  
17 warranted to clarify the accurate diagnostic efficiency of the automated RPR test.  
18  
19

### 20 21 22 **Author affiliations**

23  
24  
25  
26 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

27  
28 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

29  
30 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
31  
32

### 33 34 35 **Contributors**

36  
37 Hyon-Suk Kim designed and participated in all the stages of this study. Jong-Han Lee  
38  
39 participated in the experiments and in statistical analyses and draft the manuscript. Chae  
40  
41 Seung Lim and Min-Geol Lee helped to consultations of this study. All authors read and  
42  
43 approved the final manuscript.  
44  
45  
46  
47  
48  
49

### 50 51 **Funding**

52  
53 None  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Competing interests**  
5

6 None.  
7  
8  
9

10  
11 **Provenance and peer review**  
12

13 Not commissioned; externally peer reviewed.  
14  
15

16  
17 **Data sharing statement**  
18

19 No additional data are available.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep* 2011;60:133-7.
- 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLS Syphilis Serology Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 4 French P, Gomberg M, Janier M, *et al.* IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin Infect Dis* 2012;25:79-85.
- 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 8 Kim YS, Lee J, Lee HK, *et al.* [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab Med* 2009;29:331-7.
- 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
- 11 Castro RR, Prieto ES, Santo I, *et al.* Evaluation of the passive particle agglutination

- 1  
2  
3  
4 test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.  
5  
6 12 Castro R, Prieto ES, Aguas MJ, *et al.* Evaluation of the *Treponema pallidum* particle  
7 agglutination technique (TP.PA) in the diagnosis of neurosyphilis. *J Clin Lab Anal*  
8 2006;20:233-8.  
9  
10  
11  
12 13 Romanowski B, Sutherland R, Fick GH, *et al.* Serologic response to treatment of  
14 infectious syphilis. *Ann Intern Med* 1991;114:1005-9.  
15  
16  
17 14 Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a  
18 paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-  
19 8.  
20  
21  
22  
23 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with  
24 conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.  
25  
26  
27  
28 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the  
29 manual and automated serological testing methods for syphilis. *J Dermatol*  
30 2012;39:355-61.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Licence for Publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.

**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)

Kappa= 0.565

95% confidence interval: 0.422 to 0.709

<sup>1)</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were negative in TPPA test.

<sup>2)</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.

Abbreviations: RPR, rapid plasma reagin.

**Table 2** Discrepant RPR results to treponemal test for diagnosis of syphilis

Case No.	Age /Sex	RPR card test	Automated RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 3** Comparison of non-treponemal RPR tests according to *Treponema pallidum* particle agglutination (TPPA) test results

TPPA positive (n=59)	HBI HiSens Auto RPR		TPPA negative (n=53)	HBI HiSens Auto RPR			
	Positive	Negative		Positive	Negative		
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48
Number of observed agreements: 39 (66.1% of the observations)				Number of observed agreements: 49 (92.5% of the observations)			
Kappa= 0.296				Kappa= 0.293			
95% confidence interval: 0.118 to 0.474				95% confidence interval: -0.212 to 0.798			

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.



**Table 4** Performance characteristics of RPR tests for diagnosis syphilis

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive Negative	31 28	3 50
Sensitivity	52.5%	(95% CI: 39.1 % to 65.7 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	91.2%	(95% CI: 76.3 % to 98 %)	
Negative predictive value	64.1%	(95% CI: 52.4 % to 74.7 %)	
	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive Negative	51 8	3 50
Sensitivity	86.4%	(95% CI: 75 % to 93.9 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	94.4 %	(95% CI: 84.6 % to 98.8 %)	
Negative predictive value	86.2 %	(95% CI: 74.6 % to 93.8 %)	

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Pretreatment VDRL test value	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	1:8 reactive	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	1:1 weakly reactive	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	1:4 reactive	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	1:1 reactive	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	1:1 weakly reactive	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	1:1 weakly reactive	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	N/A	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	1:1 weakly reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	1:1 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1+	0	1:5120	1:8 reactive	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1:1 reactive	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	1:32 reactive	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	1:1 reactive	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	1:1 reactive	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	1:1 weakly reactive	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	1:2 reactive	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	1:4 reactive	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	1:8 reactive	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	1:8 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	1:16 reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	1:16 reactive	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	1:8 reactive	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	1:16 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination; N/A, not applicable.

1  
2  
3  
4 **Original article**  
5  
6  
7

8 **Comparison of an automated rapid plasma reagin (RPR) test to the conventional RPR**  
9 **card test in syphilis testing**  
10  
11  
12

13  
14  
15 Jong-Han Lee,<sup>1</sup> Chae Seung Lim,<sup>1</sup> Min-Geol Lee,<sup>2</sup> Hyon-Suk Kim<sup>3</sup>  
16  
17

18  
19  
20 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

21 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

22 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Correspondence: Hyon-Suk Kim

34 E-mail: kimhs54@yuhs.ac

35  
36  
37 Tel: (+82) 2-2228-2443

38  
39 Fax: (+82) 2-364-1583

40  
41  
42 Department of Laboratory Medicine, Yonsei University College of Medicine

43  
44 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea  
45  
46  
47

48 Running title: Automated RPR test for syphilis testing

49  
50 Number of words: 2,164; Number of abstract: 270

51  
52  
53 0 Figures, 5 Tables, and 16 References  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** We compared the automated non-treponemal reagin (rapid plasma reagin, RPR) test to the conventional RPR card test for usefulness in clinical applications.

**Setting:** A comparative study of lab methods using clinical specimens in a single institute.

**Participants:** A total of 112 serum samples including 59 TPPA- (*Treponema pallidum* particle agglutination) positive and 53 TPPA-negative specimens were included for this evaluation.

**Outcome measures:** HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) was compared to Macro-Vue RPR Card Tests (Becton Dickinson BD Microbiology Systems, Sparks, MD, USA). Treponemal-specific tests were performed by Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan). The percent agreement, kappa value, and overall sensitivity and specificity were compared between the two RPR tests. Also, seroconversion rates after treatment were compared by each RPR test.

**Results:** The agreement of both RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709). Sensitivity and specificity of the automated RPR test to TPPA was 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively, while the same values for the conventional RPR card test were 86.4% (95% CI: 75%-93.9%) and 94.3% (95%CI: 84.3%-98.8%), respectively. The conventional RPR card test showed overall higher positivity than the automated RPR test, whereas the automated RPR test showed more seroconversion changes (43.5%, 10/23) than the **conventional** RPR card test (4.3%, 1/23) in treated patients.

**Conclusions:** The automated RPR test showed overall lower sensitivity compared to conventional RPR test based on treponemal test. But, the automated RPR test showed more seroconversion after treatment than the conventional RPR card test. The automated RPR test

1  
2  
3  
4 might be used to monitor treatment response, especially in the reverse screening algorithm in  
5  
6 syphilis testing.  
7  
8

9 **Key words:** Syphilis, Automated RPR (Rapid plasma reagin), RPR card, Agreement  
10  
11

### 12 **Strengths and limitations of this study**

13  
14

- 15 ■ Automated rapid plasma regain (RPR) tests have been introduced in clinical laboratories,  
16  
17 so we compared the automated test to conventional RPR card tests.  
18  
19
- 20 ■ The automated RPR showed overall lower positivity compared to the conventional RPR  
21  
22 when comparing to treponemal test, TPPA.  
23  
24
- 25 ■ The automated RPR showed higher seroconversion after treatment than the conventional  
26  
27 manual RPR. So, the automated RPR test may be used to monitor treatment response,  
28  
29 especially in the reverse screening algorithm for syphilis testing.  
30  
31
- 32 ■ Limitations of this study could be considered, including small sample size and the patient  
33  
34 groups could not accurately categorized according to the stage because of low prevalence  
35  
36 of syphilis in Korea.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Positive rates for syphilis have rapidly decreased since the 1970s in Korea, consistent with the global trend. In 2000, approximately 0.2% of the general Korean population was estimated to be syphilis-positive, and since that time, levels have appeared to have decreased, and the prevalence rate is still very low.<sup>1</sup> Despite these low rates, syphilis is an important infection because it can cause serious health problems including neurosyphilis and congenital infection. **Appropriate screening, confirmation, and follow-up protocols are required.**<sup>2-4</sup>

Serological analysis of non-treponemal reagin tests such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), and treponemal tests such as the *Treponema Pallidum* hemagglutination assay (TPHA), *Treponema pallidum* particle agglutination (TPPA) test, fluorescent treponemal antibody absorption test (FTA-ABS) and Treponema-specific antibody test have been used to diagnose and monitor syphilis infections. Recently, there have been issues regarding selection of the best algorithm for initial screening and follow-up by either non-treponemal or treponemal-specific tests.<sup>2,5,6</sup> A non-treponemal reagin test is still recommended by the CDC to be used as a first line diagnostic approach.<sup>2</sup> Two kinds of non-treponemal test have been widely used, the VDRL and RPR methods. RPR is the most common first-line non-treponemal test used to screen for syphilis infection.<sup>7</sup> Recently, automated RPR tests have been introduced but variable results were reported when comparing the automated test to conventional RPR card tests.<sup>8</sup> The automated RPR test has some advantages over the conventional RPR card test such as greater capacity to deal with a large number of samples, minimal person-to-person variation, and simple automated procedures.

The aim of this study was to evaluate the possible benefits of an automated RPR test

1  
2  
3  
4 compared to a conventional RPR card test in clinical application.  
5  
6  
7

## 8 **METHODS**

### 9 **Subjects**

10  
11  
12  
13  
14  
15 All positive sera for syphilis by one or more tests from November 2012 to April 2013 from a  
16  
17 university hospital were included along with matched controls. Remnant sera from requested  
18  
19 treponemal test after confirmation were included and preserved at -70 °C until analysis.

20  
21  
22 Patients were not categorized according to the syphilis stage due to the infrequency of  
23  
24 syphilis infection. True syphilis patients were very rare because of its low prevalence in this  
25  
26 country. This study targeted to evaluate the same RPR tests with ethically protected remnant  
27  
28 specimens. This case was Institutional Review Board (IRB) exempted in our institution. All  
29  
30 the study processes were followed by the World Medical Association Declaration of Helsinki.  
31  
32

33  
34 The automated RPR test was compared with manual card RPR Test (Becton Dickinson BD  
35  
36 Microbiology Systems, Sparks, MD, USA). A confirmatory treponemal-specific test was  
37  
38 performed by a *Treponema pallidum* particle agglutination assay (TPPA) according to the  
39  
40 manufacturer's instructions. Seroconversion rates of each non-treponemal RPR tests were  
41  
42 evaluated with 23 syphilitic patients who had medical history of syphilis treatment.  
43  
44  
45

### 46 **Serologic tests**

#### 47 **Conventional RPR card test**

48  
49  
50 The Macro-Vue RPR Card test (Becton Dickinson BD Microbiology Systems, Sparks, MD,  
51  
52 USA) uses cardiolipin antigen with a carbon particle to detect reagin. Reagin binds to the test  
53  
54 antigen, which consists of cardiolipin-lecithin-cholesterol particles, causing macroscopic  
55  
56  
57

1  
2  
3  
4 flocculation. Controls were established in each testing to confirm optimal reactivity of the  
5 antigen. The test procedure was followed according to the manufacturer's instructions.  
6  
7  
8  
9

### 10 **Automated RPR**

11  
12 HiSens Auto RPR LTIA (HBI Co., Ltd, Anyang, Korea) is a latex turbidimetric  
13 immunoassay using latex particles coated with lecithin and cardiolipin. The latex particle  
14 reacts with the reagin in the serum of syphilis patients. The 15 µL serum samples were  
15 reacted with 120 µL Hisens auto RPR LTIA R1 (buffer) and 60 µL Hisens auto RPR LTIA R2  
16 (latex reagent containing cardiolipin-lecithin-cholesterol 1.0 mg/mL) in CA-400 autoanalyzer  
17 (Furuno Electric Co., Ltd. Nishinomiya, Japan). The CA-400 photometric analyzer was used  
18 for the automated procedure and analysis. The absorbance at 600 nm was read after 5.3  
19 seconds and 10 seconds at room temperature, in duplicate. Results of the HiSens auto RPR  
20 equal to or greater than 1.0 RPR unit (R.U.) were considered as reactive RPR. The upper  
21 detection limit was 20 R.U..  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 ***Treponema pallidum* particle agglutination (TPPA)**

38  
39 The Serodia TPPA assay (Fujirebio, Inc., Tokyo, Japan) is based on the agglutination of  
40 colored gelatin particles that have been sensitized (coated) with *T. pallidum* (Nichols strain)  
41 antigen. For each specimen, a 100 µL sample of diluent and 25 µL of test specimen were  
42 mixed first and 2-fold serial dilutions were made with 25 µL of sample diluent. The sensitized  
43 particles were serially mixed in the next wells with a plate mixer for 30 seconds. After 2  
44 hours of incubation at room temperature, the result of the agglutination assay was read. The  
45 Serodia TPPA assay results were interpreted by the agglutination patterns with positive and  
46 negative controls.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Statistical analyses

The percent agreement, kappa coefficient, of automated RPR test with manual RPR card test was calculated. The overall sensitivity and specificity of each test were calculated based on the data from TPPA results. Kappa values were used to categorize results as very good (0.81 to 1.0), good (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), or poor (0 to 0.2).<sup>9</sup> The McNemar test was used to compare the seroconversion rate between the automated RPR test and the conventional manual RPR card test and was performed by SPSS Statistics Version 20 (IBM Corporation, Armonk, NY). A p-value less than 0.05 was considered statistically significant.

## RESULTS

A total of 112 serum samples from 59 syphilis patients (48±21 years-old, Male to Female = 25:34, ratio = 0.7) and 53 non-syphilitic controls (45±17 years-old, Male to Female = 27:26, ratio = 1) after treponemal test were collected from November 2012 to April 2013 in a university hospital in Korea.

The percent agreement of the two RPR tests was 78.6% (kappa: 0.565; 95% CI: 0.422-0.709, Table 1). The strength of agreement between the automated RPR test and manual RPR card test was considered to be “moderate” according to the kappa value scale. The specimens of both RPR tests positive results (n=32) showed 96.9% (31/32) TPPA-positive and both RPR negative results (n=56) showed 85.7% (48/56) TPPA-negative results.

There were 24 discrepant results (21.4%) between the two RPR tests, including 22 negative cases of HBI HiSens Auto RPR LTIA test results that showed positive results by the BD Macro-Vue RPR card test. Of these 22 discrepant results, 20 cases were TPPA-positive and 2

1  
2  
3  
4 cases were TPPA-negative, while 2 cases were positive in the HBI HiSens Auto RPR LTIA  
5  
6 test but negative in the BD Macro-Vue RPR card test. These 2 cases were negative in the  
7  
8 TPPA test. There were 4 results with discrepancies between both of the RPR tests and the  
9  
10 TPPA assay which were due to conditions other than syphilis infections (Table 2). The  
11  
12 strength of agreement between the automated RPR and manual RPR card tests was “fair”  
13  
14 (kappa value: 0.296, 59 TPPA positive results; 0.293, 53 TPPA negative results) according to  
15  
16 TPPA results (Table 3).

17  
18  
19 The overall sensitivity and specificity of the HBI HiSens Auto RPR LTIA test based on TPPA  
20  
21 results were 52.5% (95% CI: 39.1%-65.7%) and 94.3% (95%CI: 84.3%-98.8%), respectively.  
22  
23 The overall sensitivity and specificity of the BD Macro-Vue RPR card test were 86.4% (95%  
24  
25 CI: 75%-93.9%) and 94.3% (95% CI: 84.3%-98.8%), respectively (Table 4). Automated RPR  
26  
27 gave a higher seroconversion rate after syphilis treatment, with a value of 43.5% (10/23),  
28  
29 than that of the conventional RPR card test, which was 4.3% (1/23,  $p=0.004$ ) by McNemar  
30  
31 test. Detailed comparison results of treated syphilis cases are described in Table 5.  
32  
33  
34  
35  
36

## 37 **DISCUSSION**

38  
39 Manual RPR test has been used for decades, and recently the automated RPR test method  
40  
41 was launched and has been used because of its convenience in clinical settings. However,  
42  
43 there has been the need to thorough inspection and comparing results of this new automated  
44  
45 test to conventional manual RPR test in the diagnostic approaches. The treponemal test  
46  
47 results will not change even after treatment, and the patients live with positive results for the  
48  
49 remainder of their lives regardless of treatment or disease activity. Treponemal tests cannot  
50  
51 discriminate between past infections, active disease, treated patients, and non-treated  
52  
53 patients.<sup>10</sup> In contrast, non-treponemal tests can discriminate between patients who have  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 been treated during the primary or secondary stage of the disease. When the primary or  
5  
6 secondary stage of a first *T. pallidum* infection is treated, nontreponemal test titer should  
7  
8 show a 2-dilution decline after treatment, usually within 6 months.<sup>7</sup> Therefore, non-  
9  
10 treponemal test is important for managing syphilitic patients.

11  
12 We compared an automated RPR test with a conventional RPR card test in the sera confirmed  
13  
14 by TPPA. The TPPA test is also known to be less subjective than the FTA-ABS and easier to  
15  
16 read than the microhemagglutination assay for antibodies to *Treponema pallidum* (MHA-  
17  
18 TP).<sup>11</sup> TPPA has also been suggested to be applied to CSF samples to diagnose  
19  
20 neurosyphilis.<sup>12</sup>

21  
22 In our study, the conventional BD Macro-Vue RPR card test showed better sensitivity than  
23  
24 did the HBI HiSens Auto RPR LTIA test in syphilis screening. Though, the automated RPR  
25  
26 test does have some advantages in the clinical settings. For example, the automated RPR  
27  
28 test reduced the workload and overall test turn-around time. It also can deal with greater test  
29  
30 quantities in a given time than the manual RPR card test, and does not require test experts.  
31  
32 Also, we noticed that the automated RPR test could be used as a monitoring marker of  
33  
34 treatment response, especially if treponemal tests are used for first-line screening of syphilis  
35  
36 as a reverse algorithm of syphilis testing. Recently, this reverse algorithm for syphilis testing  
37  
38 has been suggested and has been adopted in many jurisdictions because this approach may be  
39  
40 more sensitive and effective than the traditional algorithm<sup>3 4 6</sup> in a low prevalence area and  
41  
42 could be automated. However, the Centers for Disease Control and Prevention (CDC) still  
43  
44 recommend screening for syphilis with a non-treponemal test first, such as RPR.<sup>2</sup>

45  
46 Our study presented that the automated RPR test showed earlier seroconversion than  
47  
48 conventional card RPR test after syphilis treatment ( $p=0.004$ ). If we adopt the reverse  
49  
50 algorithm, it could be used that the treponemal tests screen sensitively first and then the non-  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 treponemal tests accurately show negative change in treated cases. In this situation we could  
5  
6 use treponemal tests for first-line screening and non-treponemal tests for monitoring the  
7  
8 patients to see seroconversion more effectively after treatment.<sup>2 13 14</sup> Unfortunately, our study  
9  
10 had a limited number of syphilitic patients due to low prevalence rate of syphilis in our  
11  
12 country and the number of samples was small and could not be classified according to  
13  
14 syphilis stage. In fact, some late or latent syphilis cases were hard to interpret the results of  
15  
16 **non-treponemal** test after initial treatment in our study (Case No. 8 or 9 in Table 5). So,  
17  
18 further well designed studies will be needed to clarify the serologic responses of automated  
19  
20 RPR tests after treatment and according to the stage of syphilis infection.  
21  
22

23  
24 In Korea, automated RPR tests have been recently introduced in clinical laboratories and  
25  
26 evaluations comparing conventional RPR tests and VDRL tests were reported.<sup>8 15</sup> However,  
27  
28 the results were variable. Tomohiko et al. also suggested that when the automated serological  
29  
30 testing method is used in clinical settings, the same reagent should be consistently selected to  
31  
32 evaluate the changes in antibody titers because the manual serological testing method for  
33  
34 syphilis showed somewhat different results from the automated serological testing methods.<sup>16</sup>  
35  
36 In this study, we noticed moderately consistent results between automated RPR and manual  
37  
38 RPR.  
39  
40

41  
42 We found that the automated RPR has a greater processing capability within a limited time  
43  
44 and is effectively applicable. Through the reverse syphilis screening algorithm, we can  
45  
46 increase the detection sensitivity of syphilis screening by treponemal test screening initially  
47  
48 and the automated RPR test may be used after treatment for its rapid seroconversion, though  
49  
50 the sensitivity of automated RPR is lower than manual RPR.  
51

52  
53 In conclusion, the automated RPR test showed an overall lower sensitivity and similar  
54  
55 specificity compared to the conventional manual RPR card test. Therefore, we thought that  
56  
57

1  
2  
3  
4 automated RPR is not matched to use as initial screening of syphilis. However, the automated  
5  
6 RPR seems to be earlier seroconversion response in treated cases than those of conventional  
7  
8 RPR card test. If reverse algorithm is applied, sensitive treponemal tests are used as a first  
9  
10 line screening test, and then the automated RPR might be used as an adjunct to detect earlier  
11  
12 seroconversion in treated patients.

13  
14  
15 Further large-scale studies including well-categorized patients by syphilis stage are  
16  
17 warranted to clarify the accurate diagnostic efficiency of the automated RPR test.  
18  
19

### 20 21 22 **Author affiliations**

23  
24  
25  
26 <sup>1</sup>Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

27  
28 <sup>2</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea

29  
30 <sup>3</sup>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea  
31  
32

### 33 34 35 **Contributors**

36  
37 Hyon-Suk Kim designed and participated in all the stages of this study. Jong-Han Lee  
38  
39 participated in the experiments and in statistical analyses and draft the manuscript. Chae  
40  
41 Seung Lim and Min-Geol Lee helped to consultations of this study. All authors read and  
42  
43 approved the final manuscript.  
44  
45  
46  
47  
48  
49

### 50 51 **Funding**

52  
53 None  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Competing interests**  
5

6 None.  
7  
8  
9

10  
11 **Provenance and peer review**  
12

13 Not commissioned; externally peer reviewed.  
14  
15

16  
17 **Data sharing statement**  
18

19 No additional data are available.  
20  
21

22 No data sharing  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Cho YH, Kim HO, Lee JB, *et al.* Syphilis prevalence has rapidly decreased in South Korea. *Sex Transm Infect* 2003;79:323-4.
- 2 Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep* 2011;60:133-7.
- 3 Egglestone SI, Turner AJ. Serological diagnosis of syphilis. PHLS Syphilis Serology Working Group. *Commun Dis Public Health* 2000;3:158-62.
- 4 French P, Gomberg M, Janier M, *et al.* IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
- 5 Binnicker MJ. Which algorithm should be used to screen for syphilis? *Curr Opin Infect Dis* 2012;25:79-85.
- 6 Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. *J Clin Microbiol* 2012;50:2-6.
- 7 Detrick B, Hamilton RG, Folds JD. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, D.C.: ASM Press; 2006.
- 8 Kim YS, Lee J, Lee HK, *et al.* [Comparison of quantitative results among two automated Rapid Plasma Reagin (RPR) assays and a manual RPR test]. *Korean J Lab Med* 2009;29:331-7.
- 9 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 10 Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
- 11 Castro RR, Prieto ES, Santo I, *et al.* Evaluation of the passive particle agglutination

- 1  
2  
3  
4 test in the serodiagnosis and follow-up of syphilis. *Am J Clin Pathol* 2001;116:581-5.  
5  
6 12 Castro R, Prieto ES, Aguas MJ, *et al.* Evaluation of the *Treponema pallidum* particle  
7 agglutination technique (TP.PA) in the diagnosis of neurosyphilis. *J Clin Lab Anal*  
8 2006;20:233-8.  
9  
10  
11  
12 13 Romanowski B, Sutherland R, Fick GH, *et al.* Serologic response to treatment of  
14 infectious syphilis. *Ann Intern Med* 1991;114:1005-9.  
15  
16  
17 14 Sena AC, White BL, Sparling PF. Novel *Treponema pallidum* serologic tests: a  
18 paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis* 2010;51:700-  
19 8.  
20  
21  
22  
23 15 Choi SJ, Park Y, Lee EY, *et al.* Comparisons of fully automated syphilis tests with  
24 conventional VDRL and FTA-ABS tests. *Clin Biochem* 2013;46:834-7.  
25  
26  
27  
28 16 Onoe T, Honda M, Matsuo K, *et al.* Examination of the correlation between the  
29 manual and automated serological testing methods for syphilis. *J Dermatol*  
30 2012;39:355-61.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Licence for Publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where published by the BMJ Group on their behalf), and its Licensees to permit this article (if accepted) to be published in BMJ open and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence.

**Table 1** Comparison of non-treponemal RPR tests for syphilis detection

		HBI HiSens Auto RPR	
		Positive	Negative
BD Macro-Vue RPR card	Positive	32	22 <sup>1)</sup>
	Negative	2 <sup>2)</sup>	56

Number of observed agreements: 88 (78.6% of the observations)

Kappa= 0.565

95% confidence interval: 0.422 to 0.709

<sup>1)</sup> The 20 cases were positive and 2 cases (Case No. 1, 2 in Table 2) were negative in TPPA test.

<sup>2)</sup> The 2 cases (Case No. 3, 4 in Table 2) were negative in TPPA test.

Abbreviations: RPR, rapid plasma reagin.

**Table 2** Discrepant RPR results to treponemal test for diagnosis of syphilis

Case No.	Age /Sex	RPR card test	Automated RPR (RPR Unit)	TPPA	Clinical Diagnosis
1	28/F	1+	Negative	Negative	Atopic dermatitis, Anti-phospholipid syndrome
2	50/F	1+	Negative	Negative	Bronchiectasis, Secondary pulmonary hypertension
3	22/M	Negative	2.2	Negative	Behcet's disease
4	33/M	Negative	1.1	Negative	Chlamydia, Herpes penis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 3** Comparison of non-treponemal RPR tests according to *Treponema pallidum* particle agglutination (TPPA) test results

TPPA positive (n=59)				TPPA negative (n=53)			
		HBI HiSens Auto RPR				HBI HiSens Auto RPR	
		Positive	Negative			Positive	Negative
BD Macro-Vue RPR card	Positive	31	20	BD Macro-Vue RPR card	Positive	1	2
	Negative	0	8		Negative	2	48
Number of observed agreements: 39 (66.1% of the observations)				Number of observed agreements: 49 (92.5% of the observations)			
Kappa= 0.296				Kappa= 0.293			
95% confidence interval: 0.118 to 0.474				95% confidence interval: -0.212 to 0.798			

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 4** Performance characteristics of RPR tests for diagnosis syphilis

Non-treponemal tests	TPPA		
	Positive	Negative	
HBI HiSens Auto RPR	Positive	31	3
	Negative	28	50
Sensitivity	52.5%	(95% CI: 39.1 % to 65.7 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	91.2%	(95% CI: 76.3 % to 98 %)	
Negative predictive value	64.1%	(95% CI: 52.4 % to 74.7 %)	
	TPPA		
	Positive	Negative	
BD Macro-Vue RPR card	Positive	51	3
	Negative	8	50
Sensitivity	86.4%	(95% CI: 75 % to 93.9 %)	
Specificity	94.3%	(95% CI: 84.3 % to 98.8 %)	
Positive predictive value	94.4 %	(95% CI: 84.6 % to 98.8 %)	
Negative predictive value	86.2 %	(95% CI: 74.6 % to 93.8 %)	

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination.

**Table 5** Comparisons between manual and automated RPR test after initial syphilis treatment

Case No.	Age	Gender	Manual RPR	Automated RPR (R.U.)	TPPA	Pretreatment VDRL test value	Day after initial treatment	Initial treatment	Diagnosis
1	54	Male	2+	0	1:5120	1:8 reactive	939	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
2	66	Male	0.5+	0	1:640	1:1 weakly reactive	903	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
3	17	Male	2+	0	1:5120	1:4 reactive	222	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
4	62	Male	2+	0	1:640	1:1 reactive	296	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
5	68	Male	1+	0	1:320	1:1 weakly reactive	644	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
6	72	Male	1+	0	1:640	1:1 weakly reactive	28	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
7	55	Female	0	0	1:1280	N/A	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
8	56	Female	1+	0	1:5120	1:1 weakly reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
9	65	Female	2+	0	1:80	1:1 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Late syphilis
10	33	Female	1+	0	1:5120	1:8 reactive	936	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, other and unspecified
11	28	Female	2+	1	1:2560	1:1 reactive	1097	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
12	2	Male	2+	1.1	1:5120	1:32 reactive	539	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, congenital, latent
13	65	Male	3+	1.3	1:640	1:1 reactive	273	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
14	70	Male	3+	2.3	1:1280	1:1 reactive	188	Doxycycline 100 mg	Syphilis, late, latent
15	48	Female	2+	2.5	1:5120	1:1 weakly reactive	665	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis
16	36	Female	2+	3.8	1:5120	1:2 reactive	810	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
17	74	Female	4+	7.7	1:320	1:4 reactive	669	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, latent
18	25	Female	4+	8.1	1:5120	1:8 reactive	172	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
19	64	Female	4+	14.1	1:5120	1:8 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Chronic rhinitis
20	30	Male	4+	20	1:2560	1:16 reactive	7	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, late, unspecified
21	31	Female	2+	20	1:5120	1:16 reactive	3	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis with pregnancy
22	51	Female	4+	20.4	1:5120	1:8 reactive	417	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Syphilis, latent
23	37	Female	2+	25.6	1:5120	1:16 reactive	0	Penicillin G Benzathine 1.2×10 <sup>6</sup> IU	Treated syphilis

Abbreviations: RPR, rapid plasma regain; TPPA, *Treponema pallidum* particle agglutination; N/A, not applicable.

**STARD checklist for reporting of studies of diagnostic accuracy**  
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	4
<b>METHODS</b>			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	5
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	5
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	5
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	5
<i>Test methods</i>	7	The reference standard and its rationale.	6
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	5-6
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	5-6
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	N/A
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	5-6
	13	Methods for calculating test reproducibility, if done.	N/A
<b>RESULTS</b>			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	5
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	5
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	N/A
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	N/A
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	7
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	7
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	8-10